-
1
-
-
0034799299
-
Health-related quality of life in Crohn's disease: A prospective longitudinal study in 231 patients
-
DOI 10.1016/S0002-9270(01)03243-9, PII S0002927001032439
-
Blondel-Kucharski F, Chircop C, Marquis P, et al,. Health-related quality of life in Crohn's disease: a prospective longitudinal study in 231 patients. Am J Gastroenterol 2001; 96: 2915-20. (Pubitemid 32959533)
-
(2001)
American Journal of Gastroenterology
, vol.96
, Issue.10
, pp. 2915-2920
-
-
Blondel-Kucharski, F.1
Chircop, C.2
Marquis, P.3
Cortot, A.4
Baron, F.5
Gendre, J.-P.6
Colombel, J.-F.7
-
3
-
-
39449085441
-
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: An open randomised trial
-
DOI 10.1016/S0140-6736(08)60304-9, PII S0140673608603049
-
D'Haens G, Baert F, van Assche G, et al,. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-7. (Pubitemid 351284485)
-
(2008)
The Lancet
, vol.371
, Issue.9613
, pp. 660-667
-
-
D'Haens, G.1
Baert, F.2
Van Assche, G.3
Caenepeel, P.4
Vergauwe, P.5
Tuynman, H.6
De Vos, M.7
Van Deventer, S.8
Stitt, L.9
Donner, A.10
Vermeire, S.11
Van De Mierop, F.J.12
Coche, J.-C.R.13
Van Der Woude, J.14
Ochsenkuhn, T.15
Van Bodegraven, A.A.16
Van Hootegem, P.P.17
Lambrecht, G.L.18
Mana, F.19
Rutgeerts, P.20
Feagan, B.G.21
Hommes, D.22
more..
-
4
-
-
0031036786
-
Thiopurine biology and pharmacology
-
DOI 10.1016/S0165-6147(96)01007-3, PII S0165614796010073
-
Aarbakke J, Janka-Schaub G, Elion GB,. Thiopurine biology and pharmacology. Trends Pharmacol Sci 1997; 18: 3-7. (Pubitemid 27072871)
-
(1997)
Trends in Pharmacological Sciences
, vol.18
, Issue.1
, pp. 3-7
-
-
Aarbakke, J.1
Janka-Schaub, G.2
Elion, G.B.3
-
5
-
-
84989078407
-
The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine
-
Elion GB,. The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine. Ann N Y Acad Sci 1993; 685: 400-7.
-
(1993)
Ann N y Acad Sci
, vol.685
, pp. 400-407
-
-
Elion, G.B.1
-
6
-
-
79959454066
-
A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: The TARGET study
-
Newman WG, Payne K, Tricker K, et al,. A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. Pharmacogenomics 2011; 12: 815-26.
-
(2011)
Pharmacogenomics
, vol.12
, pp. 815-826
-
-
Newman, W.G.1
Payne, K.2
Tricker, K.3
-
7
-
-
0018822866
-
Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity
-
Weinshilboum RM, Sladek SL,. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-62. (Pubitemid 10061685)
-
(1980)
American Journal of Human Genetics
, vol.32
, Issue.5
, pp. 651-662
-
-
Weinshilboum, R.M.1
Sladek, S.L.2
-
8
-
-
37549016742
-
Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease
-
Lees CW, Maan AK, Hansoti B, et al,. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008; 27: 220-7.
-
(2008)
Aliment Pharmacol Ther
, vol.27
, pp. 220-227
-
-
Lees, C.W.1
Maan, A.K.2
Hansoti, B.3
-
9
-
-
51349085433
-
Sweet syndrome as a manifestation of azathioprine hypersensitivity
-
El-Azhary RA, Brunner KL, Gibson LE,. Sweet syndrome as a manifestation of azathioprine hypersensitivity. Mayo Clin Proc 2008; 83: 1026-30.
-
(2008)
Mayo Clin Proc
, vol.83
, pp. 1026-1030
-
-
El-Azhary, R.A.1
Brunner, K.L.2
Gibson, L.E.3
-
10
-
-
34250716940
-
Erythema nodosum-like eruption as a manifestation of azathioprine hypersensitivity in patients with inflammatory bowel disease
-
DOI 10.1001/archderm.143.6.744
-
de Fonclare AL, Khosrotehrani K, Aractingi S, et al,. Erythema nodosum-like eruption as a manifestation of azathioprine hypersensitivity in patients with inflammatory bowel disease. Arch Dermatol 2007; 143: 744-8. (Pubitemid 46955733)
-
(2007)
Archives of Dermatology
, vol.143
, Issue.6
, pp. 744-748
-
-
De Fonclare, A.-L.1
Khosrotehrani, K.2
Aractingi, S.3
Duriez, P.4
Cosnes, J.5
Beaugerie, L.6
-
11
-
-
33845771801
-
Acute generalized exanthematous pustulosis associated with azathioprine hypersensitivity
-
DOI 10.1111/j.1365-2230.2006.02257.x
-
Elston GE, Johnston GA, Mortimer NJ, et al,. Acute generalized exanthematous pustulosis associated with azathioprine hypersensitivity. Clin Exp Dermatol 2007; 32: 52-3. (Pubitemid 46006367)
-
(2007)
Clinical and Experimental Dermatology
, vol.32
, Issue.1
, pp. 52-53
-
-
Elston, G.E.1
Johnston, G.A.2
Mortimer, N.J.3
Harman, K.E.4
-
12
-
-
0037098931
-
Erythema gyratum repens: Arzneimittelreaktion nach azathioprin bei einer patientin mit autoimmunhepatitis typ I
-
DOI 10.1007/s00063-002-1175-3
-
Gunther R, Nasser S, Hinrichsen H, et al,. Erythema gyratum repens: drug reaction following azathioprine administration in a patient with type I autoimmune hepatitis. Med Klin (Munich) 2002; 97: 414-7. (Pubitemid 34803352)
-
(2002)
Medizinische Klinik
, vol.97
, Issue.7
, pp. 414-417
-
-
Gunther, R.1
Nasser, S.2
Hinrichsen, H.3
Folsch, U.R.4
-
15
-
-
33845310903
-
Incidence and Risk Factors for Herpes Zoster Among Patients With Inflammatory Bowel Disease
-
DOI 10.1016/j.cgh.2006.09.019, PII S1542356506009475
-
Gupta G, Lautenbach E, Lewis JD,. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 1483-90. (Pubitemid 44880029)
-
(2006)
Clinical Gastroenterology and Hepatology
, vol.4
, Issue.12
, pp. 1483-1490
-
-
Gupta, G.1
Lautenbach, E.2
Lewis, J.D.3
-
16
-
-
0021131001
-
Adverse effects of azathioprine
-
Lawson DH, Lovatt GE, Gurton CS, et al,. Adverse effects of azathioprine. Adverse Drug React Acute Poisoning Rev 1984; 3: 161-71. (Pubitemid 14001001)
-
(1984)
Adverse Drug Reactions and Acute Poisoning Review
, vol.3
, Issue.3
, pp. 161-171
-
-
Lawson, D.H.1
Lovatt, G.E.2
Gurton, C.S.3
Hennings, R.C.4
-
17
-
-
67349134712
-
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
-
Rahier JF, Ben-Horin S, Chowers Y, et al,. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3: 47-91.
-
(2009)
J Crohns Colitis
, vol.3
, pp. 47-91
-
-
Rahier, J.F.1
Ben-Horin, S.2
Chowers, Y.3
-
18
-
-
84885140694
-
-
FDA. US Food and Drug administration Accessed November 11, 2013
-
FDA. US Food and Drug administration. FDA product information for IMURAN. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 016324s034s035lbl.pdf. Accessed November 11, 2013.
-
FDA Product Information for IMURAN
-
-
-
19
-
-
55149118807
-
Risk of nonmelanoma skin cancer with azathioprine use
-
Maddox JS, Soltani K,. Risk of nonmelanoma skin cancer with azathioprine use. Inflamm Bowel Dis 2008; 14: 1425-31.
-
(2008)
Inflamm Bowel Dis
, vol.14
, pp. 1425-1431
-
-
Maddox, J.S.1
Soltani, K.2
-
20
-
-
33744547039
-
De Novo Malignancies After Kidney and Liver Transplantations: Experience on 582 Consecutive Cases
-
DOI 10.1016/j.transproceed.2006.02.016, PII S0041134506001072
-
Baccarani U, Adani GL, Montanaro D, et al,. De novo malignancies after kidney and liver transplantations: experience on 582 consecutive cases. Transplant Proc 2006; 38: 1135-7. (Pubitemid 43815876)
-
(2006)
Transplantation Proceedings
, vol.38
, Issue.4
, pp. 1135-1137
-
-
Baccarani, U.1
Adani, G.L.2
Montanaro, D.3
Risaliti, A.4
Lorenzin, D.5
Avellini, C.6
Tulissi, P.7
Groppuzzo, M.8
Curro, G.9
Luvisetto, F.10
Beltrami, A.11
Bresadola, V.12
Viale, P.L.13
Bresadola, F.14
-
21
-
-
1442311442
-
Skin cancers in renal-transplant recipients occur more frequently than previously recognized in a temperate climate
-
DOI 10.1097/01.TP.0000108491.62935.DF
-
Bordea C, Wojnarowska F, Millard PR, et al,. Skin cancers in renal-transplant recipients occur more frequently than previously recognized in a temperate climate. Transplantation 2004; 77: 574-9. (Pubitemid 38282815)
-
(2004)
Transplantation
, vol.77
, Issue.4
, pp. 574-579
-
-
Bordea, C.1
Wojnarowska, F.2
Millard, P.R.3
Doll, H.4
Welsh, K.5
Morris, P.J.6
-
22
-
-
0029070647
-
Malignant disease in patients with long-term renal transplants
-
Gaya SB, Rees AJ, Lechler RI, et al,. Malignant disease in patients with long-term renal transplants. Transplantation 1995; 59: 1705-9.
-
(1995)
Transplantation
, vol.59
, pp. 1705-1709
-
-
Gaya, S.B.1
Rees, A.J.2
Lechler, R.I.3
-
23
-
-
33644924057
-
A population-based study of skin cancer incidence and prevalence in renal transplant recipients
-
DOI 10.1111/j.1365-2133.2005.07021.x
-
Moloney FJ, Comber H, O'Lorcain P, et al,. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006; 154: 498-504. (Pubitemid 43382659)
-
(2006)
British Journal of Dermatology
, vol.154
, Issue.3
, pp. 498-504
-
-
Moloney, F.J.1
Comber, H.2
O'Lorcain, P.3
O'Kelly, P.4
Conlon, P.J.5
Murphy, G.M.6
-
25
-
-
0015840007
-
Risk of cancer in renal-transplant recipients
-
Hoover R, Fraumeni JF Jr,. Risk of cancer in renal-transplant recipients. Lancet 1973; 2: 55-7.
-
(1973)
Lancet
, vol.2
, pp. 55-57
-
-
Hoover, R.1
Fraumeni, Jr.J.F.2
-
27
-
-
33746866362
-
Azathioprine in dermatology: The past, the present, and the future
-
DOI 10.1016/j.jaad.2005.07.059, PII S0190962205023844
-
Patel AA, Swerlick RA, McCall CO,. Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol 2006; 55: 369-89. (Pubitemid 44189574)
-
(2006)
Journal of the American Academy of Dermatology
, vol.55
, Issue.3
, pp. 369-389
-
-
Patel, A.A.1
Swerlick, R.A.2
McCall, C.O.3
-
28
-
-
0027731258
-
Incidence and treatment of neoplasia after transplantation
-
Penn I,. Incidence and treatment of neoplasia after transplantation. J Heart Lung Transplant 1993; 12: S328-36. (Pubitemid 24018966)
-
(1993)
Journal of Heart and Lung Transplantation
, vol.12
, Issue.6
-
-
Penn, I.1
-
29
-
-
0032811701
-
Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases
-
Asten P, Barrett J, Symmons D,. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999; 26: 1705-14. (Pubitemid 29367309)
-
(1999)
Journal of Rheumatology
, vol.26
, Issue.8
, pp. 1705-1714
-
-
Asten, P.1
Barrett, J.2
Symmons, D.3
-
30
-
-
0022004061
-
Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment
-
DOI 10.1016/0002-9343(85)90245-1
-
Kinlen LJ,. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985; 78: 44-9. (Pubitemid 15167365)
-
(1985)
American Journal of Medicine
, vol.78
, Issue.1 A
, pp. 44-49
-
-
Kinlen, L.J.1
-
31
-
-
0018599063
-
Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs
-
Kinlen LJ, Sheil AG, Peto J, et al,. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J 1979; 2: 1461-6. (Pubitemid 10162309)
-
(1979)
British Medical Journal
, vol.2
, Issue.6203
, pp. 1461-1466
-
-
Kinlen, L.J.1
Sheil, A.G.R.2
Peto, J.3
Doll, R.4
-
32
-
-
0031912356
-
Lymphocyte subsets and Langerhans cells in sun-protected and sun- exposed skin of immunosuppressed renal allograft recipients
-
DOI 10.1016/S0190-9622(98)70536-5
-
Galvao MM, Sotto MN, Kihara SM, et al,. Lymphocyte subsets and Langerhans cells in sun-protected and sun-exposed skin of immunosuppressed renal allograft recipients. J Am Acad Dermatol 1998; 38: 38-44. (Pubitemid 28100463)
-
(1998)
Journal of the American Academy of Dermatology
, vol.38
, Issue.1
, pp. 38-44
-
-
Galvao, M.M.1
Sotto, M.N.2
Kihara, S.M.3
Rivitti, E.A.4
Sabbaga, E.5
-
33
-
-
24944519200
-
Medicine: Azathioprine and UVA light generate mutagenic oxidative DNA damage
-
DOI 10.1126/science.1114233
-
O'Donovan P, Perrett CM, Zhang X, et al,. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309: 1871-4. (Pubitemid 41325100)
-
(2005)
Science
, vol.309
, Issue.5742
, pp. 1871-1874
-
-
O'Donovan, P.1
Perrett, C.M.2
Zhang, X.3
Montaner, B.4
Xu, Y.-Z.5
Harwood, C.A.6
McGregor, J.M.7
Walker, S.L.8
Hanaoka, F.9
Karran, P.10
-
34
-
-
79960286604
-
Nonmelanoma skin cancers in four IBD patients on treatment with immunosuppressive agents
-
Angelucci E, Cesarini M, Vernia P,. Nonmelanoma skin cancers in four IBD patients on treatment with immunosuppressive agents. Inflamm Bowel Dis 2011; 17: 1827-9.
-
(2011)
Inflamm Bowel Dis
, vol.17
, pp. 1827-1829
-
-
Angelucci, E.1
Cesarini, M.2
Vernia, P.3
-
35
-
-
0035131123
-
Inflammatory bowel disease, azathioprine and skin cancer: Case report and literature review
-
DOI 10.1097/00042737-200102000-00017
-
Austin AS, Spiller RC,. Inflammatory bowel disease, azathioprine and skin cancer: case report and literature review. Eur J Gastroenterol Hepatol 2001; 13: 193-4. (Pubitemid 32158215)
-
(2001)
European Journal of Gastroenterology and Hepatology
, vol.13
, Issue.2
, pp. 193-194
-
-
Austin, A.S.1
Spiller, R.C.2
-
36
-
-
77956656196
-
Multiple cutaneous malignancies arising in a patient with Crohn disease treated with concomitant azathioprine and antitumour necrosis factor-alpha
-
Fogo AJ, Hunt JB, Clement M,. Multiple cutaneous malignancies arising in a patient with Crohn disease treated with concomitant azathioprine and antitumour necrosis factor-alpha. Clin Exp Dermatol 2010; 35: 793-5.
-
(2010)
Clin Exp Dermatol
, vol.35
, pp. 793-795
-
-
Fogo, A.J.1
Hunt, J.B.2
Clement, M.3
-
37
-
-
77349117814
-
Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease
-
Long MD, Herfarth HH, Pipkin CA, et al,. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010; 8: 268-74.
-
(2010)
Clin Gastroenterol Hepatol
, vol.8
, pp. 268-274
-
-
Long, M.D.1
Herfarth, H.H.2
Pipkin, C.A.3
-
38
-
-
79952457521
-
Multiple and fulminant cutaneous squamous cell carcinomas in a Crohn's disease patient treated with immunosuppressants and adalimumab
-
Nancey S, Boschetti G, Cotte E, et al,. Multiple and fulminant cutaneous squamous cell carcinomas in a Crohn's disease patient treated with immunosuppressants and adalimumab. Inflamm Bowel Dis 2011; 17: 1060-1.
-
(2011)
Inflamm Bowel Dis
, vol.17
, pp. 1060-1061
-
-
Nancey, S.1
Boschetti, G.2
Cotte, E.3
-
39
-
-
79955025395
-
Risk of nonmelanoma skin cancer in patients with inflammatory bowel disease who use thiopurines is not increased
-
e441; author reply 450-441
-
van Schaik FD, van Oijen MG, Smeets HM, et al,. Risk of nonmelanoma skin cancer in patients with inflammatory bowel disease who use thiopurines is not increased. Clin Gastroenterol Hepatol 2011; 9: 449-50. e441; author reply 450-441
-
(2011)
Clin Gastroenterol Hepatol
, vol.9
, pp. 449-450
-
-
Van Schaik, F.D.1
Van Oijen, M.G.2
Smeets, H.M.3
-
40
-
-
0022410723
-
Extraintestinal cancers in inflammatory bowel disease
-
DOI 10.1002/1097-0142(19851215)56:12 <2914::AID-CNCR2820561232>3.0. CO;2-J
-
Greenstein AJ, Gennuso R, Sachar DB, et al,. Extraintestinal cancers in inflammatory bowel disease. Cancer 1985; 56: 2914-21. (Pubitemid 16216306)
-
(1985)
Cancer
, vol.56
, Issue.12
, pp. 2914-2921
-
-
Greenstein, A.J.1
Gennuso, R.2
Sachar, D.B.3
-
41
-
-
0028815367
-
Cancer in patients with ulcerative colitis
-
Mellemkjaer L, Olsen JH, Frisch M, et al,. Cancer in patients with ulcerative colitis. Int J Cancer 1995; 60: 330-3.
-
(1995)
Int J Cancer
, vol.60
, pp. 330-333
-
-
Mellemkjaer, L.1
Olsen, J.H.2
Frisch, M.3
-
42
-
-
0026100447
-
Extracolonic malignancies in inflammatory bowel disease
-
Ekbom A, Helmick C, Zack M, et al,. Extracolonic malignancies in inflammatory bowel disease. Cancer 1991; 67: 2015-9.
-
(1991)
Cancer
, vol.67
, pp. 2015-2019
-
-
Ekbom, A.1
Helmick, C.2
Zack, M.3
-
43
-
-
0036024192
-
Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine
-
Fraser AG, Orchard TR, Robinson EM, et al,. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 2002; 16: 1225-32.
-
(2002)
Aliment Pharmacol Ther
, vol.16
, pp. 1225-1232
-
-
Fraser, A.G.1
Orchard, T.R.2
Robinson, E.M.3
-
44
-
-
84856193112
-
Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: A cohort study
-
Setshedi M, Epstein D, Winter TA, et al,. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol 2012; 27: 385-9.
-
(2012)
J Gastroenterol Hepatol
, vol.27
, pp. 385-389
-
-
Setshedi, M.1
Epstein, D.2
Winter, T.A.3
-
45
-
-
80054862378
-
Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease
-
e1625
-
Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al,. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011; 141: 1621-8, e1625.
-
(2011)
Gastroenterology
, vol.141
, pp. 1621-1628
-
-
Peyrin-Biroulet, L.1
Khosrotehrani, K.2
Carrat, F.3
-
46
-
-
68949122579
-
Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine
-
Guenova E, Lichte V, Hoetzenecker W, et al,. Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine. Melanoma Res 2009; 19: 271-3.
-
(2009)
Melanoma Res
, vol.19
, pp. 271-273
-
-
Guenova, E.1
Lichte, V.2
Hoetzenecker, W.3
-
47
-
-
79951771271
-
Regression of advanced melanoma upon withdrawal of immunosuppression: Case series and literature review
-
Dillon P, Thomas N, Sharpless N, et al,. Regression of advanced melanoma upon withdrawal of immunosuppression: case series and literature review. Med Oncol 2010; 27: 1127-32.
-
(2010)
Med Oncol
, vol.27
, pp. 1127-1132
-
-
Dillon, P.1
Thomas, N.2
Sharpless, N.3
-
48
-
-
77954316696
-
Primary cutaneous lymphoma associated with Epstein-Barr virus and azathioprine therapy
-
McAleer MA, D'Arcy CA, Mulligan NJ, et al,. Primary cutaneous lymphoma associated with Epstein-Barr virus and azathioprine therapy. Clin Exp Dermatol 2010; 35: 674-6.
-
(2010)
Clin Exp Dermatol
, vol.35
, pp. 674-676
-
-
McAleer, M.A.1
D'Arcy, C.A.2
Mulligan, N.J.3
-
49
-
-
22644446331
-
Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine
-
DOI 10.1136/gut.2004.049460
-
Kandiel A, Fraser AG, Korelitz BI, et al,. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54: 1121-5. (Pubitemid 41025906)
-
(2005)
Gut
, vol.54
, Issue.8
, pp. 1121-1125
-
-
Kandiel, A.1
Fraser, A.G.2
Korelitz, B.I.3
Brensinger, C.4
Lewis, J.D.5
-
50
-
-
67949112671
-
Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: A meta-analysis
-
Siegel CA, Marden SM, Persing SM, et al,. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009; 7: 874-81.
-
(2009)
Clin Gastroenterol Hepatol
, vol.7
, pp. 874-881
-
-
Siegel, C.A.1
Marden, S.M.2
Persing, S.M.3
-
51
-
-
33846448180
-
Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease
-
DOI 10.1345/aph.1H219
-
Masunaga Y, Ohno K, Ogawa R, et al,. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother 2007; 41: 21-8. (Pubitemid 46145952)
-
(2007)
Annals of Pharmacotherapy
, vol.41
, Issue.1
, pp. 21-28
-
-
Masunaga, Y.1
Ohno, K.2
Ogawa, R.3
Hashiguchi, M.4
Echizen, H.5
Ogata, H.6
-
52
-
-
82955195113
-
Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease
-
Herrinton LJ, Liu L, Weng X, et al,. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol 2011; 106: 2146-53.
-
(2011)
Am J Gastroenterol
, vol.106
, pp. 2146-2153
-
-
Herrinton, L.J.1
Liu, L.2
Weng, X.3
-
53
-
-
80051480954
-
Risk of malignant lymphoma in patients with inflammatory bowel diseases: A Dutch nationwide study
-
Vos AC, Bakkal N, Minnee RC, et al,. Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study. Inflamm Bowel Dis 2011; 17: 1837-45.
-
(2011)
Inflamm Bowel Dis
, vol.17
, pp. 1837-1845
-
-
Vos, A.C.1
Bakkal, N.2
Minnee, R.C.3
-
54
-
-
70449100743
-
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study
-
Beaugerie L, Brousse N, Bouvier AM, et al,. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-25.
-
(2009)
Lancet
, vol.374
, pp. 1617-1625
-
-
Beaugerie, L.1
Brousse, N.2
Bouvier, A.M.3
-
55
-
-
80053484439
-
British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011
-
Meggitt SJ, Anstey AV, Mohd Mustapa MF, et al,. British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011. Br J Dermatol 2011; 165: 711-34.
-
(2011)
Br J Dermatol
, vol.165
, pp. 711-734
-
-
Meggitt, S.J.1
Anstey, A.V.2
Mohd Mustapa, M.F.3
-
56
-
-
0037108888
-
Interaction of dihydrofolate reductase with methotrexate: Ensemble and single-molecule kinetics
-
DOI 10.1073/pnas.172501499
-
Rajagopalan PT, Zhang Z, McCourt L, et al,. Interaction of dihydrofolate reductase with methotrexate: ensemble and single-molecule kinetics. Proc Natl Acad Sci USA 2002; 99: 13481-6. (Pubitemid 35215407)
-
(2002)
Proceedings of the National Academy of Sciences of the United States of America
, vol.99
, Issue.21
, pp. 13481-13486
-
-
Rajagopalan, P.T.R.1
Zhang, Z.2
McCourt, L.3
Dwyer, M.4
Benkovic, S.J.5
Hammes, G.G.6
-
57
-
-
11444251484
-
The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules
-
DOI 10.1016/j.clim.2004.09.001, PII S1521661604002748
-
Johnston A, Gudjonsson JE, Sigmundsdottir H, et al,. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005; 114: 154-63. (Pubitemid 40082381)
-
(2005)
Clinical Immunology
, vol.114
, Issue.2
, pp. 154-163
-
-
Johnston, A.1
Gudjonsson, J.E.2
Sigmundsdottir, H.3
Runar Ludviksson, B.4
Valdimarsson, H.5
-
59
-
-
33845666783
-
Three cases of toxic skin eruptions associated with methotrexate and a compilation of methotrexate-induced skin eruptions
-
Scheinfeld N,. Three cases of toxic skin eruptions associated with methotrexate and a compilation of methotrexate-induced skin eruptions. Dermatol Online J 2006; 12: 15.
-
(2006)
Dermatol Online J
, vol.12
, pp. 15
-
-
Scheinfeld, N.1
-
60
-
-
0031811423
-
Methotrexate induces apoptotic cell death in human keratinocytes
-
DOI 10.1007/s004030050298
-
Heenen M, Laporte M, Noel JC, et al,. Methotrexate induces apoptotic cell death in human keratinocytes. Arch Dermatol Res 1998; 290: 240-5. (Pubitemid 28301549)
-
(1998)
Archives of Dermatological Research
, vol.290
, Issue.5
, pp. 240-245
-
-
Heenen, M.1
Laporte, M.2
Noel, J.-C.3
De Graef, C.4
-
61
-
-
0023221735
-
Methotrexate-induced epidermal necrosis
-
DOI 10.1111/j.1365-2133.1987.tb04907.x
-
Harrison PV,. Methotrexate-induced epidermal necrosis. Br J Dermatol 1987; 116: 867-9. (Pubitemid 17075408)
-
(1987)
British Journal of Dermatology
, vol.116
, Issue.6
, pp. 867-869
-
-
Harrison, P.V.1
-
62
-
-
0033764093
-
Stevens-Johnson syndrome-like exanthema secondary to methotrexate histologically simulating acute graft-versus-host disease
-
Hani N, Casper C, Groth W, et al,. Stevens-Johnson syndrome-like exanthema secondary to methotrexate histologically simulating acute graft-versus-host disease. Eur J Dermatol 2000; 10: 548-50.
-
(2000)
Eur J Dermatol
, vol.10
, pp. 548-550
-
-
Hani, N.1
Casper, C.2
Groth, W.3
-
63
-
-
0027309532
-
Stevens-Johnson syndrome associated with methotrexate treatment for non-Hodgkin's lymphoma
-
Cuthbert RJ, Craig JI, Ludlam CA,. Stevens-Johnson syndrome associated with methotrexate treatment for non-Hodgkin's lymphoma. Ulster Med J 1993; 62: 95-7. (Pubitemid 23177061)
-
(1993)
Ulster Medical Journal
, vol.62
, Issue.1
, pp. 95-97
-
-
Cuthbert, R.J.G.1
Craig, J.I.O.2
Ludlam, C.A.3
-
64
-
-
77949911624
-
Erythema gyratum repens-like eruption occurring in resolving psoriasis during methotrexate therapy
-
Singal A, Sonthalia S, Pandhi D,. Erythema gyratum repens-like eruption occurring in resolving psoriasis during methotrexate therapy. Int J Dermatol 2010; 49: 306-7.
-
(2010)
Int J Dermatol
, vol.49
, pp. 306-307
-
-
Singal, A.1
Sonthalia, S.2
Pandhi, D.3
-
65
-
-
0005694025
-
Methotrexate-associated lymphoproliferative disorders
-
Harris N.L. Swerdlow S.H. eds. 1st ed. Lyon: IARC press
-
Jaffe ES, Harris NL, Stein H, et al,. Methotrexate-associated lymphoproliferative disorders. In:, Harris NL, Swerdlow SH, eds. World Health Organisation Classification of Tumours: Pathology and Genetics-Tumours of Haematopoetic and Lymphoid Tissue. 1st ed. Lyon: IARC press, 2001; 270-1.
-
(2001)
World Health Organisation Classification of Tumours: Pathology and Genetics-Tumours of Haematopoetic and Lymphoid Tissue
, pp. 270-271
-
-
Jaffe, E.S.1
Harris, N.L.2
Stein, H.3
-
66
-
-
35148830443
-
Reversal of multifocal cutaneous lymphoproliferative disease associated with Epstein-Barr virus after withdrawal of methotrexate therapy for rheumatoid arthritis
-
DOI 10.1016/j.jaad.2005.09.015, PII S0190962205030069
-
Maruani A, Wierzbicka E, Machet MC, et al,. Reversal of multifocal cutaneous lymphoproliferative disease associated with Epstein-Barr virus after withdrawal of methotrexate therapy for rheumatoid arthritis. J Am Acad Dermatol 2007; 57: S69-71. (Pubitemid 47552632)
-
(2007)
Journal of the American Academy of Dermatology
, vol.57
, Issue.5 SUPPL.
-
-
Maruani, A.1
Wierzbicka, E.2
Machet, M.-C.3
Abdallah-Lotf, M.4
De Muret, A.5
Machet, L.6
-
67
-
-
0029953901
-
Reversible cutaneous lymphoma occurring during methotrexate therapy
-
Viraben R, Brousse P, Lamant L,. Reversible cutaneous lymphoma occurring during methotrexate therapy. Br J Dermatol 1996; 135: 116-8. (Pubitemid 26225129)
-
(1996)
British Journal of Dermatology
, vol.135
, Issue.1
, pp. 116-118
-
-
Viraben, R.1
Brousse, P.2
Lamant, L.3
-
68
-
-
79951886446
-
Primary cutaneous Epstein-Barr virus-associated B-cell lymphoma arising at the site of subcutaneous injections of methotrexate
-
Giard C, Avenel-Audran M, Croue A, et al,. Primary cutaneous Epstein-Barr virus-associated B-cell lymphoma arising at the site of subcutaneous injections of methotrexate. J Clin Oncol 2010; 28: e717-8.
-
(2010)
J Clin Oncol
, vol.28
-
-
Giard, C.1
Avenel-Audran, M.2
Croue, A.3
-
69
-
-
45349083403
-
Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate
-
DOI 10.1002/art.23716
-
Buchbinder R, Barber M, Heuzenroeder L, et al,. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 2008; 59: 794-9. (Pubitemid 351847561)
-
(2008)
Arthritis Care and Research
, vol.59
, Issue.6
, pp. 794-799
-
-
Buchbinder, R.1
Barber, M.2
Heuzenroeder, L.3
Wluka, A.E.4
Giles, G.5
Hall, S.6
Harkness, A.7
Lewis, D.8
Littlejohn, G.9
Miller, M.H.10
Ryan, P.F.J.11
Jolley, D.12
-
70
-
-
75149161836
-
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
-
Dignass A, Van Assche G, Lindsay JO, et al,. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4: 28-62.
-
(2010)
J Crohns Colitis
, vol.4
, pp. 28-62
-
-
Dignass, A.1
Van Assche, G.2
Lindsay, J.O.3
-
71
-
-
0035045816
-
Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis
-
D'Haens G, Lemmens L, Geboes K, et al,. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120: 1323-9. (Pubitemid 32322305)
-
(2001)
Gastroenterology
, vol.120
, Issue.6
, pp. 1323-1329
-
-
D'Haens, G.1
Lemmens, L.2
Geboes, K.3
Vandeputte, L.4
Van Acker, F.5
Mortelmans, L.6
Peeters, M.7
Vermeire, S.8
Penninckx, F.9
Nevens, F.10
Hiele, M.11
Rutgeerts, P.12
-
73
-
-
0028292007
-
Cyclosporine in severe ulcerative colitis refractory to steroid therapy
-
DOI 10.1056/NEJM199406303302601
-
Lichtiger S, Present DH, Kornbluth A, et al,. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-5. (Pubitemid 24188135)
-
(1994)
New England Journal of Medicine
, vol.330
, Issue.26
, pp. 1841-1845
-
-
Lichtiger, S.1
Present, D.H.2
Kornbluth, A.3
Gelernt, I.4
Bauer, J.5
Galler, G.6
Michelassi, F.7
Hanauer, S.8
-
74
-
-
84885139150
-
-
FDA
-
FDA. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2009/050715s027,050716s028lbl.pdf.
-
-
-
-
75
-
-
0025326783
-
Side-effect profile of cyclosporin A in patients treated for psoriasis
-
DOI 10.1111/j.1365-2133.1990.tb02882.x
-
Krupp P, Monka C,. Side-effect profile of cyclosporin A in patients treated for psoriasis. Br J Dermatol 1990; 122 (Suppl. 36): 47-56. (Pubitemid 20176063)
-
(1990)
British Journal of Dermatology
, vol.122
, Issue.SUPPL. 36
, pp. 47-56
-
-
Krupp, P.1
Monka, C.2
-
76
-
-
77952628621
-
Posttransplant cutaneous T-cell lymphoma: Case reports and review of the association of calcineurin inhibitor use with posttransplant lymphoproliferative disease risk
-
Pomerantz RG, Campbell LS, Jukic DM, et al,. Posttransplant cutaneous T-cell lymphoma: case reports and review of the association of calcineurin inhibitor use with posttransplant lymphoproliferative disease risk. Arch Dermatol 2010; 146: 513-6.
-
(2010)
Arch Dermatol
, vol.146
, pp. 513-516
-
-
Pomerantz, R.G.1
Campbell, L.S.2
Jukic, D.M.3
-
77
-
-
33645012428
-
Primary cutaneous T-cell lymphoma occurring after organ transplantation
-
Ravat FE, Spittle MF, Russell-Jones R,. Primary cutaneous T-cell lymphoma occurring after organ transplantation. J Am Acad Dermatol 2006; 54: 668-75.
-
(2006)
J Am Acad Dermatol
, vol.54
, pp. 668-675
-
-
Ravat, F.E.1
Spittle, M.F.2
Russell-Jones, R.3
-
78
-
-
34250218557
-
Ocular involvement by T-cell post-transplant lymphoproliferative disorder of cutaneous origin [6]
-
DOI 10.1080/00313020701329831, PII 778818363
-
Velankar MM, Kini AR,. Ocular involvement by T-cell post-transplant lymphoproliferative disorder of cutaneous origin. Pathology 2007; 39: 369-71. (Pubitemid 46897589)
-
(2007)
Pathology
, vol.39
, Issue.3
, pp. 369-371
-
-
Velankar, M.M.1
Kini, A.R.2
-
79
-
-
46049098155
-
Mycosis fungoides in a lung transplant recipient with advanced ciclosporin nephropathy: Management with mechlorethamine and subsequent renal transplantation
-
DOI 10.1159/000128283
-
Laffitte E, Venetz JP, Aubert JD, et al,. Mycosis fungoides in a lung transplant recipient with advanced ciclosporin nephropathy: management with mechlorethamine and subsequent renal transplantation. Dermatology 2008; 217: 87-8. (Pubitemid 351896579)
-
(2008)
Dermatology
, vol.217
, Issue.1
, pp. 87-88
-
-
Laffitte, E.1
Venetz, J.-P.2
Aubert, J.-D.3
Duchosal, M.A.4
Panizzon, R.G.5
Pascual, M.6
-
80
-
-
41149145622
-
Mycosis fungoides after solid-organ transplantation: Report of 2 new cases
-
DOI 10.1097/DAD.0b013e318164cf6e, PII 0000037220080400000011
-
Rodriguez-Gil Y, Palencia SI, Lopez-Rios F, et al,. Mycosis fungoides after solid-organ transplantation: report of 2 new cases. Am J Dermatopathol 2008; 30: 150-5. (Pubitemid 351441988)
-
(2008)
American Journal of Dermatopathology
, vol.30
, Issue.2
, pp. 150-155
-
-
Rodriguez-Gil, Y.1
Palencia, S.-I.2
Lopez-Rios, F.3
Ortiz, P.L.4
Rodriguez-Peralto, J.L.5
-
81
-
-
0036909110
-
Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis
-
DOI 10.1046/j.1365-2036.2002.01385.x
-
Domenech E, Garcia-Planella E, Bernal I, et al,. Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2002; 16: 2061-5. (Pubitemid 36009169)
-
(2002)
Alimentary Pharmacology and Therapeutics
, vol.16
, Issue.12
, pp. 2061-2065
-
-
Domenech, E.1
Garcia-Planella, E.2
Bernal, I.3
Rosinach, M.4
Cabrie, E.5
Fluvia, L.6
Boix, J.7
Gassull, M.A.8
-
82
-
-
33846242958
-
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn's Disease: The CHARM Trial
-
DOI 10.1053/j.gastro.2006.11.041, PII S0016508506025224
-
Colombel JF, Sandborn WJ, Rutgeerts P, et al,. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65. (Pubitemid 46108762)
-
(2007)
Gastroenterology
, vol.132
, Issue.1
, pp. 52-65
-
-
Colombel, J.1
Sandborn, W.J.2
Rutgeerts, P.3
Enns, R.4
Hanauer, S.B.5
Panaccione, R.6
Schreiber, S.7
Byczkowski, D.8
Li, J.9
Kent, J.D.10
Pollack, P.F.11
-
83
-
-
0037018761
-
Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial
-
DOI 10.1016/S0140-6736(02)08512-4
-
Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9. (Pubitemid 34621118)
-
(2002)
Lancet
, vol.359
, Issue.9317
, pp. 1541-1549
-
-
Hanauer, S.B.1
Feagan, B.G.2
Lichtenstein, G.R.3
Mayer, L.F.4
Schreiber, S.5
Colombel, J.F.6
Rachmilewitz, D.7
Wolf, D.C.8
Olson, A.9
Bao, W.10
Rutgeerts, P.11
-
84
-
-
34249281002
-
Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial
-
DOI 10.1136/gut.2006.106781
-
Sandborn WJ, Hanauer SB, Rutgeerts P, et al,. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232-9. (Pubitemid 47300424)
-
(2007)
Gut
, vol.56
, Issue.9
, pp. 1232-1239
-
-
Sandborn, W.J.1
Hanauer, S.B.2
Rutgeerts, P.3
Fedorak, R.N.4
Lulcas, M.5
MacIntosh, D.G.6
Panaccione, R.7
Wolf, D.8
Kent, J.D.9
Bittle, B.10
Li, J.11
Pollack, P.F.12
-
85
-
-
28844473957
-
Infliximab for induction and maintenance therapy for ulcerative colitis
-
DOI 10.1056/NEJMoa050516
-
Rutgeerts P, Sandborn WJ, Feagan BG, et al,. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76. (Pubitemid 41770166)
-
(2005)
New England Journal of Medicine
, vol.353
, Issue.23
, pp. 2462-2476
-
-
Rutgeerts, P.1
Sandborn, W.J.2
Feagan, B.G.3
Reinisch, W.4
Olson, A.5
Johanns, J.6
Travers, S.7
Rachmilewitz, D.8
Hanauer, S.B.9
Lichtenstein, G.R.10
De Villiers, W.J.S.11
Present, D.12
Sands, B.E.13
Colombel, J.F.14
-
86
-
-
84856163835
-
Adalimumab Induces and Maintains Clinical Remission in Patients with Moderate-to-Severe Ulcerative Colitis
-
Sandborn WJ, Van Assche G, Reinisch W, et al,. Adalimumab Induces and Maintains Clinical Remission in Patients with Moderate-to-Severe Ulcerative Colitis. Gastroenterology 2012; 142: 257-65.e1-3.
-
(2012)
Gastroenterology
, vol.142
-
-
Sandborn, W.J.1
Van Assche, G.2
Reinisch, W.3
-
87
-
-
33645958908
-
Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: A randomized placebo-controlled trial
-
Lemann M, Mary JY, Duclos B, et al,. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006; 130: 1054-61.
-
(2006)
Gastroenterology
, vol.130
, pp. 1054-1061
-
-
Lemann, M.1
Mary, J.Y.2
Duclos, B.3
-
88
-
-
77950988234
-
Infliximab, azathioprine, or combination therapy for Crohn's disease
-
Colombel JF, Sandborn WJ, Reinisch W, et al,. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
-
(2010)
N Engl J Med
, vol.362
, pp. 1383-1395
-
-
Colombel, J.F.1
Sandborn, W.J.2
Reinisch, W.3
-
89
-
-
75449114677
-
Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease
-
Baert F, Moortgat L, Van Assche G, et al,. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010; 138: 463-8.
-
(2010)
Gastroenterology
, vol.138
, pp. 463-468
-
-
Baert, F.1
Moortgat, L.2
Van Assche, G.3
-
90
-
-
34547503869
-
Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based Cohort
-
DOI 10.1053/j.gastro.2007.05.051, PII S001650850701102X
-
Froslie KF, Jahnsen J, Moum BA, et al,. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-22. (Pubitemid 47187355)
-
(2007)
Gastroenterology
, vol.133
, Issue.2
, pp. 412-422
-
-
Froslie, K.F.1
Jahnsen, J.2
Moum, B.A.3
Vatn, M.H.4
-
91
-
-
70350172248
-
Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease
-
Schnitzler F, Fidder H, Ferrante M, et al,. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009; 15: 1295-301.
-
(2009)
Inflamm Bowel Dis
, vol.15
, pp. 1295-1301
-
-
Schnitzler, F.1
Fidder, H.2
Ferrante, M.3
-
92
-
-
33846950349
-
Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists
-
Lee HH, Song IH, Friedrich M, et al,. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007; 156: 486-91.
-
(2007)
Br J Dermatol
, vol.156
, pp. 486-491
-
-
Lee, H.H.1
Song, I.H.2
Friedrich, M.3
-
93
-
-
70350049105
-
Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors
-
Exarchou SA, Voulgari PV, Markatseli TE, et al,. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol 2009; 38: 328-31.
-
(2009)
Scand J Rheumatol
, vol.38
, pp. 328-331
-
-
Exarchou, S.A.1
Voulgari, P.V.2
Markatseli, T.E.3
-
94
-
-
67650227459
-
Dermatological complications and safety of anti-TNF treatments
-
Kerbleski JF, Gottlieb AB,. Dermatological complications and safety of anti-TNF treatments. Gut 2009; 58: 1033-9.
-
(2009)
Gut
, vol.58
, pp. 1033-1039
-
-
Kerbleski, J.F.1
Gottlieb, A.B.2
-
95
-
-
0034268094
-
Long term safety of infliximab
-
Schaible TF,. Long term safety of infliximab. Can J Gastroenterol. 2000; 14 (Suppl. C): 29C-32C.
-
(2000)
Can J Gastroenterol
, vol.14
, Issue.SUPPL. C
-
-
Schaible, T.F.1
-
96
-
-
0037640033
-
Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy
-
DOI 10.1159/000069965
-
Devos SA, Van Den Bossche N, De Vos M, et al,. Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology 2003; 206: 388-90. (Pubitemid 36677038)
-
(2003)
Dermatology
, vol.206
, Issue.4
, pp. 388-390
-
-
Devos, S.A.1
Van Den Bossche, N.2
De Vos, M.3
Naeyaert, J.M.4
-
97
-
-
0036149052
-
Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis
-
DOI 10.1136/gut.0780047..
-
Chan AT, Cleeve V, Daymond TJ,. Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J 2002; 78: 47-8. (Pubitemid 34074917)
-
(2002)
Postgraduate Medical Journal
, vol.78
, Issue.915
, pp. 47-48
-
-
Chan, A.T.Y.1
Cleeve, V.2
Daymond, T.J.3
-
98
-
-
0033059667
-
Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity
-
DOI 10.1038/9544
-
Bickerstaff MC, Botto M, Hutchinson WL, et al,. Serum amyloid P compo-nent controls chromatin degradation and prevents antinuclear autoim-munity. Nat Med 1999; 5: 694-7. (Pubitemid 29289434)
-
(1999)
Nature Medicine
, vol.5
, Issue.6
, pp. 694-697
-
-
Bickerstaff, M.C.M.1
Botto, M.2
Hutchinson, W.L.3
Herbert, J.4
Tennent, G.A.5
Bybee, A.6
Mitchell, D.A.7
Cook, H.T.8
Butler, P.J.G.9
Walport, M.J.10
Pepys, M.B.11
-
99
-
-
0034467152
-
Role of apoptosis in autoimmunity
-
DOI 10.1023/A:1009692902805
-
Lorenz HM, Herrmann M, Winkler T, et al,. Role of apoptosis in autoimmunity. Apoptosis 2000; 5: 443-9. (Pubitemid 32162628)
-
(2000)
Apoptosis
, vol.5
, Issue.5
, pp. 443-449
-
-
Lorenz, H.-M.1
Herrmann, M.2
Winkler, T.3
Gaipl, U.4
Kalden, J.R.5
-
100
-
-
14144256349
-
Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFα
-
DOI 10.1136/ard.2004.024182
-
Eriksson C, Engstrand S, Sundqvist KG, et al,. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 2005; 64: 403-7. (Pubitemid 40283050)
-
(2005)
Annals of the Rheumatic Diseases
, vol.64
, Issue.3
, pp. 403-407
-
-
Eriksson, C.1
Engstrand, S.2
Sundqvist, K.-G.3
Rantapaa-Dahlqvist, S.4
-
101
-
-
30844473089
-
Drug-induced lupus erythematosus
-
DOI 10.1080/08916930500285857, PII G8720721118114
-
Sarzi-Puttini P, Atzeni F, Capsoni F, et al,. Drug-induced lupus erythematosus. Autoimmunity 2005; 38: 507-18. (Pubitemid 43101785)
-
(2005)
Autoimmunity
, vol.38
, Issue.7
, pp. 507-518
-
-
Sarzi-Puttini, P.1
Atzeni, F.2
Capsoni, F.3
Lubrano, E.4
Doria, A.5
-
102
-
-
48949117157
-
Anti-nuclear antibodies, acti-DNA and C4 complement evolution in rheumatiod arthritis and ankylosing spondylitis treated with TNF-α blockers
-
Gonnet-Gracia C, Barnetche T, Richez C, et al,. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers. Clin Exp Rheumatol 2008; 26: 401-7. (Pubitemid 352003207)
-
(2008)
Clinical and Experimental Rheumatology
, vol.26
, Issue.3
, pp. 401-407
-
-
Gonnet-Gracia, C.1
Barnetche, T.2
Richez, C.3
Blanco, P.4
Dehais, J.5
Schaeverbecke, T.6
-
104
-
-
0032741665
-
The paradigm of Th1 and Th2 cytokines: Its relevance to autoimmunity and allergy
-
Singh VK, Mehrotra S, Agarwal SS,. The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol Res 1999; 20: 147-61.
-
(1999)
Immunol Res
, vol.20
, pp. 147-161
-
-
Singh, V.K.1
Mehrotra, S.2
Agarwal, S.S.3
-
105
-
-
27744533607
-
Proinflammatory cytokine (IL-1β, IL-6, IL-12, IL-18 and TNF-α) levels in sera of patients with subacute cutaneous lupus erythematosus (SCLE)
-
DOI 10.1016/j.imlet.2005.08.001, PII S0165247805001860
-
Maczynska I, Millo B, Ratajczak-Stefanska V, et al,. Proinflammatory cytokine (IL-1beta, IL-6, IL-12, IL-18 and TNF-alpha) levels in sera of patients with subacute cutaneous lupus erythematosus (SCLE). Immunol Lett 2006; 102: 79-82. (Pubitemid 41606043)
-
(2006)
Immunology Letters
, vol.102
, Issue.1
, pp. 79-82
-
-
Maczynska, I.1
Millo, B.2
Ratajczak-Stefanska, V.3
Maleszka, R.4
Szych, Z.5
Kurpisz, M.6
Giedrys-Kalemba, S.7
-
106
-
-
0028143211
-
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis
-
DOI 10.1016/S0140-6736(94)90628-9
-
Elliott MJ, Maini RN, Feldmann M, et al,. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10. (Pubitemid 24317629)
-
(1994)
Lancet
, vol.344
, Issue.8930
, pp. 1105-1110
-
-
Elliott, M.J.1
Maini, R.N.2
Feldmann, M.3
Kalden, J.R.4
Antoni, C.5
Smolen, J.S.6
Leeb, B.7
Breedveld, F.C.8
Macfarlane, J.D.9
Bijl, H.10
Woody, J.N.11
-
107
-
-
0027438710
-
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α
-
DOI 10.1002/art.1780361206
-
Elliott MJ, Maini RN, Feldmann M, et al,. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36: 1681-90. (Pubitemid 23360007)
-
(1993)
Arthritis and Rheumatism
, vol.36
, Issue.12
, pp. 1681-1690
-
-
Elliott, M.J.1
Maini, R.N.2
Feldmann, M.3
Long-Fox, A.4
Charles, P.5
Katsikis, P.6
Brennan, F.M.7
Walker, J.8
Bijl, H.9
Ghrayeb, J.10
Woody, J.N.11
-
108
-
-
0031660364
-
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
-
DOI 10.1002/1529-0131(199809)41:9 <1552::AID-ART5>3.0.CO;2-W
-
Maini RN, Breedveld FC, Kalden JR, et al,. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63. (Pubitemid 28459913)
-
(1998)
Arthritis and Rheumatism
, vol.41
, Issue.9
, pp. 1552-1563
-
-
Maini, R.N.1
Breedveld, F.C.2
Kalden, J.R.3
Smolen, J.S.4
Davis, D.5
Macfarlane, J.D.6
Antoni, C.7
Leeb, B.8
Elliott, M.J.9
Woody, J.N.10
Schaible, T.F.11
Feldmann, M.12
-
109
-
-
0033763979
-
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: Findings in open-label and randomized placebo-controlled trials
-
Charles PJ, Smeenk RJ, De Jong J, et al,. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000; 43: 2383-90.
-
(2000)
Arthritis Rheum
, vol.43
, pp. 2383-2390
-
-
Charles, P.J.1
Smeenk, R.J.2
De Jong, J.3
-
110
-
-
0038109994
-
Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn's disease: A prospective cohort study
-
DOI 10.1016/S0016-5085(03)00701-7
-
Vermeire S, Noman M, Van Assche G, et al,. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003; 125: 32-9. (Pubitemid 36799104)
-
(2003)
Gastroenterology
, vol.125
, Issue.1
, pp. 32-39
-
-
Vermeire, S.1
Noman, M.2
Van Assche, G.3
Baert, F.4
Van Steen, K.5
Esters, N.6
Joossens, S.7
Bossuyt, X.8
Rutgeerts, P.9
-
111
-
-
24344450107
-
Autoantibody profile during short-term infliximab treatment for Crohn's disease: A prospective cohort study
-
DOI 10.1111/j.1365-2036.2005.02576.x
-
Atzeni F, Ardizzone S, Sarzi-Puttini P, et al,. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study. Aliment Pharmacol Ther 2005; 22: 453-61. (Pubitemid 41248113)
-
(2005)
Alimentary Pharmacology and Therapeutics
, vol.22
, Issue.5
, pp. 453-461
-
-
Atzeni, F.1
Ardizzone, S.2
Sarzi-Puttini, P.3
Colombo, E.4
Maconi, G.5
De Portu, S.6
Carrabba, M.7
Porro, G.B.8
-
112
-
-
27644548981
-
Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease
-
DOI 10.1097/01.MIB.0000186408.07769.78
-
Nancey S, Blanvillain E, Parmentier B, et al,. Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease. Inflamm Bowel Dis 2005; 11: 986-91. (Pubitemid 41580012)
-
(2005)
Inflammatory Bowel Diseases
, vol.11
, Issue.11
, pp. 986-991
-
-
Nancey, S.1
Blanvillain, E.2
Parmentier, B.3
Flourie, B.4
Bayet, C.5
Bienvenu, J.6
Fabien, N.7
-
113
-
-
84885138602
-
-
Centocor. Inquiry Number 1-729933475. Published 26 January 2009, and released to authors
-
Centocor. Inquiry Number 1-729933475. Published 26 January 2009, and released to authors.
-
-
-
-
114
-
-
47049112010
-
The role of tumor necrosis factor-alpha in systemic lupus erythematosus
-
Aringer M, Smolen JS,. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther 2008; 10: 202.
-
(2008)
Arthritis Res Ther
, vol.10
, pp. 202
-
-
Aringer, M.1
Smolen, J.S.2
-
116
-
-
71449111969
-
Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic
-
Wetter DA, Davis MD,. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 2009; 84: 979-84.
-
(2009)
Mayo Clin Proc
, vol.84
, pp. 979-984
-
-
Wetter, D.A.1
Davis, M.D.2
-
117
-
-
78650110438
-
Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent
-
Subramanian S, Yajnik V, Sands BE, et al,. Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm Bowel Dis 2011; 17: 99-104.
-
(2011)
Inflamm Bowel Dis
, vol.17
, pp. 99-104
-
-
Subramanian, S.1
Yajnik, V.2
Sands, B.E.3
-
118
-
-
37249063841
-
TNFα blockade in human diseases: An overview of efficacy and safety
-
DOI 10.1016/j.clim.2007.08.012, PII S1521661607013265
-
Lin J, Ziring D, Desai S, et al,. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008; 126: 13-30. (Pubitemid 350266448)
-
(2008)
Clinical Immunology
, vol.126
, Issue.1
, pp. 13-30
-
-
Lin, J.1
Ziring, D.2
Desai, S.3
Kim, S.4
Wong, M.5
Korin, Y.6
Braun, J.7
Reed, E.8
Gjertson, D.9
Singh, R.R.10
-
119
-
-
33745064418
-
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis
-
Schiff MH, Burmester GR, Kent JD, et al,. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 889-94.
-
(2006)
Ann Rheum Dis
, vol.65
, pp. 889-894
-
-
Schiff, M.H.1
Burmester, G.R.2
Kent, J.D.3
-
120
-
-
84885107701
-
-
FDA. US Food and Drug Administration. FDA labels for TNF inhibitors: infliximab http://www.fda. gov/cder/foi/label /2008/125057s114lbl.pdf; etanercept, http://www.fda.gov/cder/foi/ label/2008/103795s5359lbl.pdf; andcertolizumab pegol, http://www.cimzia.com/ pdf/CIMZIA%20PI%20032008.pdf. Accessed November 1, 2008
-
FDA. US Food and Drug Administration. FDA labels for TNF inhibitors: infliximab. Available at: http://www.fda.gov/cder/foi/label/2007/103772s5189lbl. pdf; adalimumab, http://www.fda.gov/cder/foi/label/2008/125057s114lbl.pdf; etanercept, http://www.fda.gov/cder/foi/label/2008/103795s5359lbl.pdf; andcertolizumab pegol, http://www.cimzia.com/pdf/CIMZIA%20PI%20032008.pdf. Accessed November 1, 2008.
-
-
-
-
121
-
-
21744446004
-
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: A French national survey
-
De Bandt M, Sibilia J, Le Loet X, et al,. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005; 7: R545-51.
-
(2005)
Arthritis Res Ther
, vol.7
-
-
De Bandt, M.1
Sibilia, J.2
Le Loet, X.3
-
122
-
-
44349171691
-
Drug-Induced Lupus due to Anti-Tumor Necrosis Factor α Agents
-
DOI 10.1016/j.semarthrit.2007.08.003, PII S0049017207001394
-
Costa MF, Said NR, Zimmermann B,. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008; 37: 381-7. (Pubitemid 351734520)
-
(2008)
Seminars in Arthritis and Rheumatism
, vol.37
, Issue.6
, pp. 381-387
-
-
Costa, M.F.1
Said, N.R.2
Zimmermann, B.3
-
123
-
-
0020056755
-
Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis
-
Yates VM, Watkinson G, Kelman A,. Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis. Br J Dermatol 1982; 106: 323-30. (Pubitemid 12177002)
-
(1982)
British Journal of Dermatology
, vol.106
, Issue.3
, pp. 323-330
-
-
Yates, V.M.1
Watkinson, G.2
Kelman, A.3
-
124
-
-
77949865934
-
The status of biologic therapies in the treatment of moderate to severe psoriasis
-
Menter A,. The status of biologic therapies in the treatment of moderate to severe psoriasis. Cutis 2009; 84: 14-24.
-
(2009)
Cutis
, vol.84
, pp. 14-24
-
-
Menter, A.1
-
125
-
-
77955924889
-
Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis
-
Menter A, Gordon KB, Leonardi CL, et al,. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol 2010; 63: 448-56.
-
(2010)
J Am Acad Dermatol
, vol.63
, pp. 448-456
-
-
Menter, A.1
Gordon, K.B.2
Leonardi, C.L.3
-
126
-
-
0345731433
-
Psoriasiform Eruption Induced by Infliximab
-
Verea MM, Del Pozo J, Yebra-Pimentel MT, et al,. Psoriasiform eruption induced by infliximab. Ann Pharmacother 2004; 38: 54-7. (Pubitemid 38018006)
-
(2004)
Annals of Pharmacotherapy
, vol.38
, Issue.1
, pp. 54-57
-
-
Verea, M.M.1
Del Pozo, J.2
Yebra-Pimentel, M.T.3
Porta, A.4
Fonseca, E.5
-
127
-
-
63849102069
-
Review article: Anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease
-
Fiorino G, Allez M, Malesci A, et al,. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009; 29: 921-7.
-
(2009)
Aliment Pharmacol Ther
, vol.29
, pp. 921-927
-
-
Fiorino, G.1
Allez, M.2
Malesci, A.3
-
128
-
-
61949136505
-
First case report of adalimumab-induced psoriasis in Crohn's disease
-
Harris MD, Richards R,. First case report of adalimumab-induced psoriasis in Crohn's disease. Am J Gastroenterol 2009; 104: 792-3.
-
(2009)
Am J Gastroenterol
, vol.104
, pp. 792-793
-
-
Harris, M.D.1
Richards, R.2
-
129
-
-
77957108223
-
Psoriatic skin lesions induced by certolizumab pegol
-
Klein RQ, Spivack J, Choate KA,. Psoriatic skin lesions induced by certolizumab pegol. Arch Dermatol 2010; 146: 1055-6.
-
(2010)
Arch Dermatol
, vol.146
, pp. 1055-1056
-
-
Klein, R.Q.1
Spivack, J.2
Choate, K.A.3
-
130
-
-
72049122955
-
Severe cutaneous psoriasis after certolizumab pegol treatment: Report of a case
-
Mocciaro F, Renna S, Orlando A, et al,. Severe cutaneous psoriasis after certolizumab pegol treatment: report of a case. Am J Gastroenterol 2009; 104: 2867-8.
-
(2009)
Am J Gastroenterol
, vol.104
, pp. 2867-2868
-
-
Mocciaro, F.1
Renna, S.2
Orlando, A.3
-
131
-
-
58849160468
-
Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: Results from the British Society for Rheumatology Biologics Register
-
Harrison MJ, Dixon WG, Watson KD, et al,. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009; 68: 209-15.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 209-215
-
-
Harrison, M.J.1
Dixon, W.G.2
Watson, K.D.3
-
132
-
-
0042887352
-
Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: A new perspective on the role of host defence in the pathogenesis of the disease?
-
DOI 10.1136/ard.62.9.829
-
Baeten D, Kruithof E, Van den Bosch F, et al,. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003; 62: 829-34. (Pubitemid 37026492)
-
(2003)
Annals of the Rheumatic Diseases
, vol.62
, Issue.9
, pp. 829-834
-
-
Baeten, D.1
Kruithof, E.2
Van Den Bosch, F.3
Van Den Bossche, N.4
Herssens, A.5
Mielants, H.6
De Keyser, F.7
Veys, E.M.8
-
133
-
-
81355151359
-
Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: A new series and a review of 120 cases from the literature
-
Cullen G, Kroshinsky D, Cheifetz AS, et al,. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther 2011; 34: 1318-27.
-
(2011)
Aliment Pharmacol Ther
, vol.34
, pp. 1318-1327
-
-
Cullen, G.1
Kroshinsky, D.2
Cheifetz, A.S.3
-
134
-
-
42749088023
-
Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy
-
Wendling D, Balblanc JC, Briancon D, et al,. Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy. Joint Bone Spine 2008; 75: 315-8.
-
(2008)
Joint Bone Spine
, vol.75
, pp. 315-318
-
-
Wendling, D.1
Balblanc, J.C.2
Briancon, D.3
-
135
-
-
33846974080
-
Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions
-
DOI 10.1001/archderm.143.2.223
-
de Gannes GC, Ghoreishi M, Pope J, et al,. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007; 143: 223-31. (Pubitemid 46294587)
-
(2007)
Archives of Dermatology
, vol.143
, Issue.2
, pp. 223-231
-
-
De Gannes, G.C.1
Ghoreishi, M.2
Pope, J.3
Russell, A.4
Bell, D.5
Adams, S.6
Shojania, K.7
Martinka, M.8
Dutz, J.P.9
-
136
-
-
37249030025
-
Psoriasiform eruptions during anti-TNF-α treatment: Psoriasis or not? [5]
-
DOI 10.1001/archderm.143.12.1593
-
Seneschal J, Lepreux S, Milpied B, et al,. Psoriasiform eruptions during anti TNF-alpha treatment: psoriasis or not? Arch Dermatol 2007; 143: 1593-5; author reply 1595. (Pubitemid 350277789)
-
(2007)
Archives of Dermatology
, vol.143
, Issue.12
, pp. 1593-1595
-
-
Seneschal, J.1
Lepreux, S.2
Milpied, B.3
Schaeverbeke, T.4
Taieb, A.5
-
137
-
-
36048994573
-
Triggering psoriasis: The role of infections and medications
-
DOI 10.1016/j.clindermatol.2007.08.015, PII S0738081X07001599
-
Fry L, Baker BS,. Triggering psoriasis: the role of infections and medications. Clin Dermatol 2007; 25: 606-15. (Pubitemid 350087607)
-
(2007)
Clinics in Dermatology
, vol.25
, Issue.6
, pp. 606-615
-
-
Fry, L.1
Baker, B.S.2
-
138
-
-
47949126329
-
Psoriasiform lesions induced by tumour necrosis factor antagonists: A skin-deep medical conundrum
-
Carter JD, Gerard HC, Hudson AP,. Psoriasiform lesions induced by tumour necrosis factor antagonists: a skin-deep medical conundrum. Ann Rheum Dis 2008; 67: 1181-3.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 1181-1183
-
-
Carter, J.D.1
Gerard, H.C.2
Hudson, A.P.3
-
139
-
-
0030911341
-
Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling
-
DOI 10.1084/jem.185.9.1573
-
Cope AP, Liblau RS, Yang XD, et al,. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 1997; 185: 1573-84. (Pubitemid 27203254)
-
(1997)
Journal of Experimental Medicine
, vol.185
, Issue.9
, pp. 1573-1584
-
-
Cope, A.P.1
Liblau, R.S.2
Yang, X.-D.3
Congia, M.4
Laudanna, C.5
Schreiber, R.D.6
Probert, L.7
Kollias, G.8
McDevitt, H.O.9
-
140
-
-
14744276518
-
Cross-regulation of TNF and IFN-α in autoimmune diseases
-
DOI 10.1073/pnas.0408506102
-
Palucka AK, Blanck JP, Bennett L, et al,. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA 2005; 102: 3372-7. (Pubitemid 40328052)
-
(2005)
Proceedings of the National Academy of Sciences of the United States of America
, vol.102
, Issue.9
, pp. 3372-3377
-
-
Palucka, A.K.1
Blanck, J.-P.2
Bennett, L.3
Pascual, V.4
Banchereau, J.5
-
141
-
-
33847279025
-
Pathogenesis and therapy of psoriasis
-
Lowes MA, Bowcock AM, Krueger JG,. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866-73.
-
(2007)
Nature
, vol.445
, pp. 866-873
-
-
Lowes, M.A.1
Bowcock, A.M.2
Krueger, J.G.3
-
142
-
-
22344438901
-
Plasmacytoid predendritic cells initiate psoriasis through interferon-α production
-
DOI 10.1084/jem.20050500
-
Nestle FO, Conrad C, Tun-Kyi A, et al,. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005; 202: 135-43. (Pubitemid 41002916)
-
(2005)
Journal of Experimental Medicine
, vol.202
, Issue.1
, pp. 135-143
-
-
Nestle, F.O.1
Conrad, C.2
Tun-Kyi, A.3
Homey, B.4
Gombert, M.5
Boyman, O.6
Burg, G.7
Liu, Y.-J.8
Gilliet, M.9
-
143
-
-
31144441631
-
In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: Enhanced expression in psoriatic skin
-
Piskin G, Sylva-Steenland RM, Bos JD, et al,. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006; 176: 1908-15. (Pubitemid 43134336)
-
(2006)
Journal of Immunology
, vol.176
, Issue.3
, pp. 1908-1915
-
-
Piskin, G.1
Sylva-Steenland, R.M.R.2
Bos, J.D.3
Teunissen, M.B.M.4
-
144
-
-
78649445740
-
Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: Clinical features and possible immunopathogenesis
-
Collamer AN, Battafarano DF,. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010; 40: 233-40.
-
(2010)
Semin Arthritis Rheum
, vol.40
, pp. 233-240
-
-
Collamer, A.N.1
Battafarano, D.F.2
-
145
-
-
47249159958
-
Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action
-
DOI 10.1002/art.23835
-
Collamer AN, Guerrero KT, Henning JS, et al,. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008; 59: 996-1001. (Pubitemid 351990997)
-
(2008)
Arthritis Care and Research
, vol.59
, Issue.7
, pp. 996-1001
-
-
Collamer, A.N.1
Guerrero, K.T.2
Henning, J.S.3
Battafarano, D.F.4
-
146
-
-
67650216399
-
Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases
-
Ko JM, Gottlieb AB, Kerbleski JF,. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat. 2009; 20: 100-8.
-
(2009)
J Dermatolog Treat.
, vol.20
, pp. 100-108
-
-
Ko, J.M.1
Gottlieb, A.B.2
Kerbleski, J.F.3
-
147
-
-
84860835230
-
Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: A report of 21 cases
-
Guerra I, Algaba A, Perez-Calle JL, et al,. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. Journal of Crohn's and Colitis 2012; 6: 518-23.
-
(2012)
Journal of Crohn's and Colitis
, vol.6
, pp. 518-523
-
-
Guerra, I.1
Algaba, A.2
Perez-Calle, J.L.3
-
148
-
-
79952818972
-
Psoriatic alopecia/alopecia areata-like reactions secondary to anti-tumor necrosis factor-alpha therapy: A novel cause of noncicatricial alopecia
-
Doyle LA, Sperling LC, Baksh S, et al,. Psoriatic alopecia/alopecia areata-like reactions secondary to anti-tumor necrosis factor-alpha therapy: a novel cause of noncicatricial alopecia. Am J Dermatopathol 2011; 33: 161-6.
-
(2011)
Am J Dermatopathol
, vol.33
, pp. 161-166
-
-
Doyle, L.A.1
Sperling, L.C.2
Baksh, S.3
-
149
-
-
73949130344
-
Adalimumab-induced psoriasis of the scalp with diffuse alopecia: A severe potentially irreversible cutaneous side effect of TNF-alpha blockers
-
El Shabrawi-Caelen L, La Placa M, Vincenzi C, et al,. Adalimumab-induced psoriasis of the scalp with diffuse alopecia: a severe potentially irreversible cutaneous side effect of TNF-alpha blockers. Inflamm Bowel Dis 2010; 16: 182-3.
-
(2010)
Inflamm Bowel Dis
, vol.16
, pp. 182-183
-
-
El Shabrawi-Caelen, L.1
La Placa, M.2
Vincenzi, C.3
-
150
-
-
41049110226
-
Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis
-
DOI 10.1007/s00296-007-0475-6
-
Lee YH, Woo JH, Rho YH, et al,. Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. Rheumatol Int 2008; 28: 553-9. (Pubitemid 351422618)
-
(2008)
Rheumatology International
, vol.28
, Issue.6
, pp. 553-559
-
-
Lee, Y.H.1
Woo, J.H.2
Rho, Y.H.3
Choi, S.J.4
Ji, J.D.5
Song, G.G.6
-
151
-
-
0036715313
-
Cutaneous drug eruption to infliximab: Report of 4 cases with an interface dermatitis pattern [7]
-
Vergara G, Silvestre JF, Betlloch I, et al,. Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol 2002; 138: 1258-9. (Pubitemid 35025713)
-
(2002)
Archives of Dermatology
, vol.138
, Issue.9
, pp. 1258-1259
-
-
Vergara, G.1
Silvestre, J.F.2
Betlloch, I.3
Vela, P.4
Pilar Albares, M.5
Carlos Pascual, J.6
-
152
-
-
66949122526
-
Lichen planus-like eruptions: An emerging side effect of tumor necrosis factor-alpha antagonists
-
Asarch A, Gottlieb AB, Lee J, et al,. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol 2009; 61: 104-11.
-
(2009)
J Am Acad Dermatol
, vol.61
, pp. 104-111
-
-
Asarch, A.1
Gottlieb, A.B.2
Lee, J.3
-
153
-
-
24944532440
-
Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: A prospective study
-
Flendrie M, Vissers WH, Creemers MC, et al,. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005; 7: R666-76.
-
(2005)
Arthritis Res Ther.
, vol.7
-
-
Flendrie, M.1
Vissers, W.H.2
Creemers, M.C.3
-
154
-
-
34248334541
-
Manifestations cutanées observées au cours d'un traitement par anti-TNF alpha: 11 Observations
-
DOI 10.1016/S0151-9638(07)89187-3
-
Lebas D, Staumont-Salle D, Solau-Gervais E, et al,. Cutaneous manifestations during treatment with TNF-alpha blockers: 11 cases. Ann Dermatol Venereol 2007; 134: 337-42. (Pubitemid 46731755)
-
(2007)
Annales de Dermatologie et de Venereologie
, vol.134
, Issue.4
, pp. 337-342
-
-
Lebas, D.1
Staumont-Salle, D.2
Solau-Gervais, E.3
Flipo, R.-M.4
Delaporte, E.5
-
155
-
-
53549113693
-
Clinical challenges and images in GI. Oral lichenoid reaction in a patient with Crohn's disease receiving infliximab
-
829
-
Moss AC, Treister NS, Marsee DK, et al,. Clinical challenges and images in GI. Oral lichenoid reaction in a patient with Crohn's disease receiving infliximab. Gastroenterology 2007; 132: 488, 829.
-
(2007)
Gastroenterology
, vol.132
, pp. 488
-
-
Moss, A.C.1
Treister, N.S.2
Marsee, D.K.3
-
157
-
-
34250177232
-
Etanercept-induced lichenoid reaction pattern in psoriasis
-
DOI 10.1080/09546630600967174, PII 768573866
-
Bovenschen HJ, Kop EN, Van De Kerkhof PC, et al,. Etanercept-induced lichenoid reaction pattern in psoriasis. J Dermatolog Treat. 2006; 17: 381-3. (Pubitemid 46895585)
-
(2006)
Journal of Dermatological Treatment
, vol.17
, Issue.6
, pp. 381-383
-
-
Bovenschen, J.H.1
Kop, E.N.2
Van De Kerkhof, P.C.M.3
Seyger, M.M.B.4
-
158
-
-
42149099317
-
Lichenoid reaction induced by adalimumab
-
DOI 10.1111/j.1468-3083.2007.02413.x
-
De Simone C, Caldarola G, D'Agostino M, et al,. Lichenoid reaction induced by adalimumab. J Eur Acad Dermatol Venereol 2008; 22: 626-7. (Pubitemid 351541066)
-
(2008)
Journal of the European Academy of Dermatology and Venereology
, vol.22
, Issue.5
, pp. 626-627
-
-
De Simone, C.1
Caldarola, G.2
D'agostino, M.3
Rotoli, M.4
Capizzi, R.5
Amerio, P.6
-
159
-
-
34250677788
-
Etanercept for the management of oral lichen planus
-
Yarom N,. Etanercept for the management of oral lichen planus. Am J Clin Dermatol 2007; 8: 121. (Pubitemid 46998557)
-
(2007)
American Journal of Clinical Dermatology
, vol.8
, Issue.2
, pp. 121
-
-
Yarom, N.1
-
160
-
-
0037709396
-
Atopic dermatitis-like eruption precipitated by infliximab [4]
-
Wright RC,. Atopic dermatitis-like eruption precipitated by infliximab. J Am Acad Dermatol 2003; 49: 160-1. (Pubitemid 36801660)
-
(2003)
Journal of the American Academy of Dermatology
, vol.49
, Issue.1
, pp. 160-161
-
-
Wright, R.C.1
-
161
-
-
80051489321
-
Tumor necrosis factor-alpha in vitiligo: Direct correlation between tissue levels and clinical parameters
-
Kim NH, Torchia D, Rouhani P, et al,. Tumor necrosis factor-alpha in vitiligo: direct correlation between tissue levels and clinical parameters. Cutan Ocul Toxicol. 2011; 30: 225-7.
-
(2011)
Cutan Ocul Toxicol.
, vol.30
, pp. 225-227
-
-
Kim, N.H.1
Torchia, D.2
Rouhani, P.3
-
162
-
-
80053552817
-
Worsening of vitiligo and onset of new psoriasiform dermatitis following treatment with infliximab
-
Alghamdi KM, Khurrum H, Rikabi A,. Worsening of vitiligo and onset of new psoriasiform dermatitis following treatment with infliximab. J Cutan Med Surg. 2011; 15: 280-4.
-
(2011)
J Cutan Med Surg.
, vol.15
, pp. 280-284
-
-
Alghamdi, K.M.1
Khurrum, H.2
Rikabi, A.3
-
163
-
-
33846203357
-
Infliximab-induced acne: Report of two cases [19]
-
DOI 10.1111/j.1365-2133.2006.07665.x
-
Bassi E, Poli F, Charachon A, et al,. Infliximab-induced acne: report of two cases. Br J Dermatol 2007; 156: 402-3. (Pubitemid 46095989)
-
(2007)
British Journal of Dermatology
, vol.156
, Issue.2
, pp. 402-403
-
-
Bassi, E.1
Poli, F.2
Charachon, A.3
Claudepierre, P.4
Revuz, J.5
-
164
-
-
42949160630
-
Acneiform eruption following anti-TNF-alpha treatment: A report of three cases
-
Sun G, Wasko CA, Hsu S,. Acneiform eruption following anti-TNF-alpha treatment: a report of three cases. J Drugs Dermatol 2008; 7: 69-71.
-
(2008)
J Drugs Dermatol
, vol.7
, pp. 69-71
-
-
Sun, G.1
Wasko, C.A.2
Hsu, S.3
-
165
-
-
0038772008
-
Tumor necrosis factor biology in experimental and clinical arthritis
-
DOI 10.1097/00002281-200307000-00003
-
Sfikakis PP, Kollias G,. Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol 2003; 15: 380-6. (Pubitemid 36774248)
-
(2003)
Current Opinion in Rheumatology
, vol.15
, Issue.4
, pp. 380-386
-
-
Sfikakis, P.P.1
Kollias, G.2
-
166
-
-
0141531063
-
Anti-tumor necrosis factor-α therapy-induced vasculitis: Case series
-
Jarrett SJ, Cunnane G, Conaghan PG, et al,. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 2003; 30: 2287-91. (Pubitemid 37221866)
-
(2003)
Journal of Rheumatology
, vol.30
, Issue.10
, pp. 2287-2291
-
-
Jarrett, S.J.1
Cunnane, G.2
Conaghan, P.G.3
Bingham, S.J.4
Buch, M.H.5
Quinn, M.A.6
Emery, P.7
-
167
-
-
84866387410
-
Vasculitis Associated with Tumor Necrosis Factor-alpha Inhibitors
-
Sokumbi O, Wetter DA, Makol A, et al,. Vasculitis Associated With Tumor Necrosis Factor-alpha Inhibitors. Mayo Clin Proc 2012; 87: 739-45.
-
(2012)
Mayo Clin Proc
, vol.87
, pp. 739-745
-
-
Sokumbi, O.1
Wetter, D.A.2
Makol, A.3
-
168
-
-
0347519211
-
B cell activation in rheumatoid arthritis patients under infliximab treatment
-
De Miguel S, Jover JA, Vadillo C, et al,. B cell activation in rheumatoid arthritis patients under infliximab treatment. Clin Exp Rheumatol 2003; 21: 726-32. (Pubitemid 38008755)
-
(2003)
Clinical and Experimental Rheumatology
, vol.21
, Issue.6
, pp. 726-732
-
-
De Miguel, S.1
Jover, J.A.2
Vadillo, C.3
Judez, E.4
Loza, E.5
Fernandez-Guiterrez, B.6
-
169
-
-
0036853090
-
Effectiveness of TNF-α blockade with infliximab in refractory Wegener's granulomatosis
-
Lamprecht P, Voswinkel J, Lilienthal T, et al,. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002; 41: 1303-7. (Pubitemid 35363806)
-
(2002)
Rheumatology
, vol.41
, Issue.11
, pp. 1303-1307
-
-
Lamprecht, P.1
Voswinkel, J.2
Lilienthal, T.3
Nolle, B.4
Heller, M.5
Gross, W.L.6
Gause, A.7
-
170
-
-
31444454494
-
A ring-shaped eruption
-
DOI 10.1016/j.amjmed.2005.12.002, PII S000293430501137X
-
Alexander JS, Paniker PU,. A ring-shaped eruption. Am J Med 2006; 119: 125-7. (Pubitemid 43151476)
-
(2006)
American Journal of Medicine
, vol.119
, Issue.2
, pp. 125-127
-
-
Alexander, J.S.1
Paniker, P.2
-
171
-
-
41849115630
-
Granuloma annulare induced by anti-tumour necrosis factor therapy
-
DOI 10.1136/ard.2007.075663
-
Voulgari PV, Markatseli TE, Exarchou SA, et al,. Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis 2008; 67: 567-70. (Pubitemid 351498443)
-
(2008)
Annals of the Rheumatic Diseases
, vol.67
, Issue.4
, pp. 567-570
-
-
Voulgari, P.V.1
Markatseli, T.E.2
Exarchou, S.A.3
Zioga, A.4
Drosos, A.A.5
-
172
-
-
73449120738
-
Education and imaging. Gastrointestinal: Improvement of granuloma annulare with anti-tumour necrosis factor alpha therapy for Crohn's disease
-
Fanning SB, Chapman G, Yau Y, et al,. Education and imaging. Gastrointestinal: improvement of granuloma annulare with anti-tumour necrosis factor alpha therapy for Crohn's disease. J Gastroenterol Hepatol 2010; 25: 215.
-
(2010)
J Gastroenterol Hepatol
, vol.25
, pp. 215
-
-
Fanning, S.B.1
Chapman, G.2
Yau, Y.3
-
173
-
-
0031881853
-
The interstitial granulomatous drug reaction: A distinctive clinical and pathological entity
-
DOI 10.1111/j.1600-0560.1998.tb01693.x
-
Magro CM, Crowson AN, Schapiro BL,. The interstitial granulomatous drug reaction: a distinctive clinical and pathological entity. J Cutan Pathol 1998; 25: 72-8. (Pubitemid 28073644)
-
(1998)
Journal of Cutaneous Pathology
, vol.25
, Issue.2
, pp. 72-78
-
-
Magro, C.M.1
Crowson, A.N.2
Schapiro, B.L.3
-
175
-
-
0037863769
-
Interstitial granulomatous dermatitis with plaques and arthritis
-
Banuls J, Betlloch I, Botella R, et al,. Interstitial granulomatous dermatitis with plaques and arthritis. Eur J Dermatol 2003; 13: 308-10. (Pubitemid 36683448)
-
(2003)
European Journal of Dermatology
, vol.13
, Issue.3
, pp. 308-310
-
-
Banuls, J.1
Betlloch, I.2
Botella, R.3
Jimenez, M.J.4
Blanes, M.5
Pascual, J.C.6
Belinchon, I.7
Silvestre, J.F.8
-
176
-
-
0030001522
-
Interstitial granulomatous dermatitis with arthritis
-
DOI 10.1016/S0190-9622(96)90272-8
-
Long D, Thiboutot DM, Majeski JT, et al,. Interstitial granulomatous dermatitis with arthritis. J Am Acad Dermatol 1996; 34: 957-61. (Pubitemid 26170759)
-
(1996)
Journal of the American Academy of Dermatology
, vol.34
, Issue.6
, pp. 957-961
-
-
Long, D.1
Thiboutot, D.M.2
Majeski, J.T.3
Vasily, D.B.4
Helm, K.F.5
-
177
-
-
0030023290
-
Granuloma annulare and necrobiosis lipoidica tissue reactions as a manifestation of systemic disease
-
DOI 10.1016/S0046-8177(96)90137-9
-
Magro CM, Crowson AN, Regauer S,. Granuloma annulare and necrobiosis lipoidica tissue reactions as a manifestation of systemic disease. Hum Pathol 1996; 27: 50-6. (Pubitemid 26015580)
-
(1996)
Human Pathology
, vol.27
, Issue.1
, pp. 50-56
-
-
Magro, C.M.1
Crowson, A.N.2
Regauer, S.3
-
178
-
-
0036621140
-
Interstitial granulomatous dermatitis with plaques
-
Tomasini C, Pippione M,. Interstitial granulomatous dermatitis with plaques. J Am Acad Dermatol 2002; 46: 892-9.
-
(2002)
J Am Acad Dermatol
, vol.46
, pp. 892-899
-
-
Tomasini, C.1
Pippione, M.2
-
179
-
-
0028089859
-
The histopathologic spectrum of palisaded neutrophilic and granulomatous dermatitis in patients with collagen vascular disease
-
DOI 10.1001/archderm.130.10.1278
-
Chu P, Connolly MK, LeBoit PE,. The histopathologic spectrum of palisaded neutrophilic and granulomatous dermatitis in patients with collagen vascular disease. Arch Dermatol 1994; 130: 1278-83. (Pubitemid 24313287)
-
(1994)
Archives of Dermatology
, vol.130
, Issue.10
, pp. 1278-1283
-
-
Chu, P.1
Connolly, M.K.2
LeBoit, P.E.3
-
180
-
-
33244478108
-
Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor α inhibitors
-
DOI 10.1001/archderm.142.2.198
-
Deng A, Harvey V, Sina B, et al,. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Dermatol 2006; 142: 198-202. (Pubitemid 43276531)
-
(2006)
Archives of Dermatology
, vol.142
, Issue.2
, pp. 198-202
-
-
Deng, A.1
Harvey, V.2
Sina, B.3
Strobel, D.4
Badros, A.5
Junkins-Hopkins, J.M.6
Samuels, A.7
Oghilikhan, M.8
Gaspari, A.9
-
181
-
-
84855254283
-
Interstitial granulomatous dermatitis: Another clinical variant
-
Patsatsi A, Kyriakou A, Triantafyllidou E, et al,. Interstitial granulomatous dermatitis: another clinical variant. Case Rep Dermatol. 2011; 3: 195-200.
-
(2011)
Case Rep Dermatol.
, vol.3
, pp. 195-200
-
-
Patsatsi, A.1
Kyriakou, A.2
Triantafyllidou, E.3
-
183
-
-
0031867753
-
Accelerated cutaneous nodulosis during methotrexate therapy in a patient with rheumatoid arthritis
-
Williams FM, Cohen PR, Arnett FC,. Accelerated cutaneous nodulosis during methotrexate therapy in a patient with rheumatoid arthritis. J Am Acad Dermatol 1998; 39: 359-62. (Pubitemid 28367316)
-
(1998)
Journal of the American Academy of Dermatology
, vol.39
, Issue.2
, pp. 359-362
-
-
Williams, F.M.1
Cohen, P.R.2
Arnett, F.C.3
-
184
-
-
46749109197
-
Interstitial granulomatous drug reaction to anakinra
-
DOI 10.1016/j.jaad.2007.11.004, PII S0190962207022803
-
Regula CG, Hennessy J, Clarke LE, et al,. Interstitial granulomatous drug reaction to anakinra. J Am Acad Dermatol 2008; 59: S25-7. (Pubitemid 351952429)
-
(2008)
Journal of the American Academy of Dermatology
, vol.59
, Issue.2 SUPPL.
-
-
Regula, C.G.1
Hennessy, J.2
Clarke, L.E.3
Adams, D.R.4
Ioffreda, M.D.5
Graber, E.M.6
Helm, K.F.7
-
185
-
-
72949115077
-
Interstitial granulomatous dermatitis in rheumatoid arthritis responsive to etanercept
-
Zoli A, Massi G, Pinnelli M, et al,. Interstitial granulomatous dermatitis in rheumatoid arthritis responsive to etanercept. Clin Rheumatol 2010; 29: 99-101.
-
(2010)
Clin Rheumatol
, vol.29
, pp. 99-101
-
-
Zoli, A.1
Massi, G.2
Pinnelli, M.3
-
186
-
-
10444238497
-
Palisaded neutrophilic and granulomatous dermatitis: An unusual cutaneous manifestation of immune-mediated disorders
-
DOI 10.1016/j.semarthrit.2004.06.001, PII S0049017204001337
-
Bremner R, Simpson E, White CR, et al,. Palisaded neutrophilic and granulomatous dermatitis: an unusual cutaneous manifestation of immune-mediated disorders. Semin Arthritis Rheum 2004; 34: 610-6. (Pubitemid 39643123)
-
(2004)
Seminars in Arthritis and Rheumatism
, vol.34
, Issue.3
, pp. 610-616
-
-
Bremner, R.1
Simpson, E.2
White Jr., C.R.3
Morrison, L.4
Deodhar, A.5
-
189
-
-
47149092108
-
Skin manifestations of inflammatory bowel disease
-
DOI 10.1016/j.clindermatol.2007.10.018, PII S0738081X07002416
-
Timani S, Mutasim DF,. Skin manifestations of inflammatory bowel disease. Clin Dermatol 2008; 26: 265-73. (Pubitemid 351978196)
-
(2008)
Clinics in Dermatology
, vol.26
, Issue.3
, pp. 265-273
-
-
Timani, S.1
Mutasim, D.F.2
-
191
-
-
0035044890
-
The prevalence of extraintestinal diseases in inflammatory bowel disease: A population-based study
-
DOI 10.1016/S0002-9270(01)02319-X, PII S000292700102319X
-
Bernstein CN, Blanchard JF, Rawsthorne P, et al,. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001; 96: 1116-22. (Pubitemid 32319146)
-
(2001)
American Journal of Gastroenterology
, vol.96
, Issue.4
, pp. 1116-1122
-
-
Bernstein, C.N.1
Blanchard, J.F.2
Rawsthorne, P.3
Yu, N.4
-
192
-
-
0027193194
-
Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients
-
Farmer RG, Easley KA, Rankin GB,. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci 1993; 38: 1137-46. (Pubitemid 23175139)
-
(1993)
Digestive Diseases and Sciences
, vol.38
, Issue.6
, pp. 1137-1146
-
-
Farmer, R.G.1
Easley, K.A.2
Rankin, G.B.3
-
193
-
-
67650137726
-
Mucocutaneous manifestations in inflammatory bowel disease
-
Yuksel I, Basar O, Ataseven H, et al,. Mucocutaneous manifestations in inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 546-50.
-
(2009)
Inflamm Bowel Dis
, vol.15
, pp. 546-550
-
-
Yuksel, I.1
Basar, O.2
Ataseven, H.3
-
195
-
-
0036123608
-
Traitement d'un syndrome de Sweet et d'un érythéme noueux compliquant une maladie de Crohn par anti-TNFα (infliximab)
-
Vanbiervliet G, Anty R, Schneider S, et al,. Sweet's syndrome and erythema nodosum associated with Crohn's disease treated by infliximab. Gastroenterol Clin Biol 2002; 26: 295-7. (Pubitemid 34408024)
-
(2002)
Gastroenterologie Clinique et Biologique
, vol.26
, Issue.3
, pp. 295-297
-
-
Vanbiervliet, G.1
Anty, R.2
Schneider, S.3
Arab, K.4
Rampal, P.5
Hebuterne, X.6
-
196
-
-
84873622497
-
Drug-induced erythema nodosum after the administration of certolizumab in Crohn's disease
-
Biedermann L, Kerl K, Rogler G, et al,. Drug-induced erythema nodosum after the administration of certolizumab in Crohn's disease. Inflamm Bowel Dis 2013; 19: E4-6.
-
(2013)
Inflamm Bowel Dis
, vol.19
-
-
Biedermann, L.1
Kerl, K.2
Rogler, G.3
-
197
-
-
43449131274
-
Erythema nodosum associated with infliximab therapy
-
Rosen T, Martinelli P,. Erythema nodosum associated with infliximab therapy. Dermatol Online J 2008; 14: 3.
-
(2008)
Dermatol Online J
, vol.14
, pp. 3
-
-
Rosen, T.1
Martinelli, P.2
-
198
-
-
35648973826
-
Psoriasis, erythema nodosum, and nummular eczema onset in an ankylosing spondylitis patient treated with infliximab [2]
-
DOI 10.1080/03009740701288173, PII 783464666
-
Delle Sedie A, Bazzichi L, Bombardieri S, et al,. Psoriasis, erythema nodosum, and nummular eczema onset in an ankylosing spondylitis patient treated with infliximab. Scand J Rheumatol 2007; 36: 403-4. (Pubitemid 350034813)
-
(2007)
Scandinavian Journal of Rheumatology
, vol.36
, Issue.5
, pp. 403-404
-
-
Sedie, A.D.1
Bazzichi, L.2
Bombardieri, S.3
Riente, L.4
-
199
-
-
1542329560
-
Failure of infliximab treatment and occurrence of erythema nodosum during therapy in two patients with Behçet's disease [7]
-
DOI 10.1093/rheumatology/keh056
-
Yucel AE, Kart-Koseoglu H, Akova YA, et al,. Failure of infliximab treatment and occurrence of erythema nodosum during therapy in two patients with Behcet's disease. Rheumatology (Oxford) 2004; 43: 394-6. (Pubitemid 38313200)
-
(2004)
Rheumatology
, vol.43
, Issue.3
, pp. 394-396
-
-
Yucel, A.E.1
Kart-Koseoglu, H.2
Akova, Y.A.3
Demirhan, B.4
Boyacioglu, S.5
-
200
-
-
33646696885
-
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
-
DOI 10.1001/jama.295.19.2275
-
Bongartz T, Sutton AJ, Sweeting MJ, et al,. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85. (Pubitemid 43736578)
-
(2006)
Journal of the American Medical Association
, vol.295
, Issue.19
, pp. 2275-2285
-
-
Bongartz, T.1
Sutton, A.J.2
Sweeting, M.J.3
Buchan, I.4
Matteson, E.L.5
Montori, V.6
-
201
-
-
78751685797
-
Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: Meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data
-
Askling J, Fahrbach K, Nordstrom B, et al,. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011; 20: 119-30.
-
(2011)
Pharmacoepidemiol Drug Saf
, vol.20
, pp. 119-130
-
-
Askling, J.1
Fahrbach, K.2
Nordstrom, B.3
-
202
-
-
82255175193
-
Cutaneous lymphoma in a patient with ulcerative colitis after immunosuppressive therapy
-
Rojas-Feria M, Eslam M, Castro-Fernandez M, et al,. Cutaneous lymphoma in a patient with ulcerative colitis after immunosuppressive therapy. J Crohns Colitis 2011; 5: 608-11.
-
(2011)
J Crohns Colitis
, vol.5
, pp. 608-611
-
-
Rojas-Feria, M.1
Eslam, M.2
Castro-Fernandez, M.3
-
203
-
-
82955195113
-
Role of Thiopurine and Anti-TNF Therapy in Lymphoma in Inflammatory Bowel Disease
-
Herrinton LJ, Liu L, Weng X, et al,. Role of Thiopurine and Anti-TNF Therapy in Lymphoma in Inflammatory Bowel Disease. Am J Gastroenterol 2011; 106: 2146-53.
-
(2011)
Am J Gastroenterol
, vol.106
, pp. 2146-2153
-
-
Herrinton, L.J.1
Liu, L.2
Weng, X.3
-
204
-
-
0036675378
-
Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis
-
author reply 2259
-
Kent PD, Davis JM 3rd, Davis MD, et al,. Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis. Arthritis Rheum 2002; 46: 2257-8; author reply 2259.
-
(2002)
Arthritis Rheum
, vol.46
, pp. 2257-2258
-
-
Kent, P.D.1
Davis III, J.M.2
Davis, M.D.3
-
205
-
-
77956386272
-
Development of pyoderma gangrenosum during therapy with infliximab
-
Jaimes-Lopez N, Molina V, Arroyave JE, et al,. Development of pyoderma gangrenosum during therapy with infliximab. J Dermatol Case Rep 2009; 3: 20-3.
-
(2009)
J Dermatol Case Rep
, vol.3
, pp. 20-23
-
-
Jaimes-Lopez, N.1
Molina, V.2
Arroyave, J.E.3
-
206
-
-
41349088375
-
Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease
-
DOI 10.1053/j.gastro.2008.01.012, PII S0016508508000516
-
Toruner M, Loftus EV Jr, Harmsen WS, et al,. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-36. (Pubitemid 351451967)
-
(2008)
Gastroenterology
, vol.134
, Issue.4
, pp. 929-936
-
-
Toruner, M.1
Loftus Jr., E.V.2
Harmsen, W.S.3
Zinsmeister, A.R.4
Orenstein, R.5
Sandborn, W.J.6
Colombel, J.7
Egan, L.J.8
-
207
-
-
34247884424
-
Natalizumab for the Treatment of Active Crohn's Disease: Results of the ENCORE Trial
-
DOI 10.1053/j.gastro.2007.03.024, PII S0016508507005380
-
Targan SR, Feagan BG, Fedorak RN, et al,. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007; 132: 1672-83. (Pubitemid 46695722)
-
(2007)
Gastroenterology
, vol.132
, Issue.5
, pp. 1672-1683
-
-
Targan, S.R.1
Feagan, B.G.2
Fedorak, R.N.3
Lashner, B.A.4
Panaccione, R.5
Present, D.H.6
Spehlmann, M.E.7
Rutgeerts, P.J.8
Tulassay, Z.9
Volfova, M.10
Wolf, D.C.11
Hernandez, C.12
Bornstein, J.13
Sandborn, W.J.14
-
208
-
-
27644441529
-
Natalizumab induction and maintenance therapy for Crohn's disease
-
DOI 10.1056/NEJMoa043335
-
Sandborn WJ, Colombel JF, Enns R, et al,. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-25. (Pubitemid 41565956)
-
(2005)
New England Journal of Medicine
, vol.353
, Issue.18
, pp. 1912-1925
-
-
Sandborn, W.J.1
Colombel, J.F.2
Enns, R.3
Feagan, B.G.4
Hanauer, S.B.5
Lawrance, I.C.6
Panaccione, R.7
Sanders, M.8
Schreiber, S.9
Targan, S.10
Van Deventer, S.11
Goldblum, R.12
Despain, D.13
Hogge, G.S.14
Rutgeerts, P.15
-
209
-
-
22844445230
-
Progressive multifocal leukoencephalopathy in a patient treated with natalizumab
-
DOI 10.1056/NEJMoa051847
-
Langer-Gould A, Atlas SW, Green AJ, et al,. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353: 375-81. (Pubitemid 41132342)
-
(2005)
New England Journal of Medicine
, vol.353
, Issue.4
, pp. 375-381
-
-
Langer-Gould, A.1
Atlas, S.W.2
Green, A.J.3
Bollen, A.W.4
Pelletier, D.5
-
210
-
-
33644605483
-
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy
-
Yousry TA, Major EO, Ryschkewitsch C, et al,. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354: 924-33.
-
(2006)
N Engl J Med
, vol.354
, pp. 924-933
-
-
Yousry, T.A.1
Major, E.O.2
Ryschkewitsch, C.3
-
211
-
-
33750972887
-
Infusion-related hypersensitivity reactions during natalizumab treatment
-
DOI 10.1212/01.wnl.0000242629.66372.33, PII 0000611420061114000048
-
Phillips JT, O'Connor PW, Havrdova E, et al,. Infusion-related hypersensitivity reactions during natalizumab treatment. Neurology 2006; 67: 1717-8. (Pubitemid 44747962)
-
(2006)
Neurology
, vol.67
, Issue.9
, pp. 1717-1718
-
-
Phillips, J.T.1
O'Connor, P.W.2
Havrdova, E.3
Hutchinson, M.4
Kappos, L.5
Miller, D.H.6
Polman, C.H.7
Lublin, F.D.8
Giovannoni, G.9
Wajgt, A.10
Lynn, F.11
Panzara, M.A.12
Sandrock, A.W.13
-
212
-
-
34548602366
-
Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies
-
DOI 10.1001/archneur.64.9.1331
-
Krumbholz M, Pellkofer H, Gold R, et al,. Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol 2007; 64: 1331-3. (Pubitemid 47403090)
-
(2007)
Archives of Neurology
, vol.64
, Issue.9
, pp. 1331-1333
-
-
Krumbholz, M.1
Pellkofer, H.2
Gold, R.3
Hoffmann, L.A.4
Hohlfeld, R.5
Kumpfel, T.6
-
213
-
-
53049091561
-
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
-
Sandborn WJ, Feagan BG, Fedorak RN, et al,. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008; 135: 1130-41.
-
(2008)
Gastroenterology
, vol.135
, pp. 1130-1141
-
-
Sandborn, W.J.1
Feagan, B.G.2
Fedorak, R.N.3
-
214
-
-
84866754101
-
Effectiveness and Safety of Ustekinumab as Rescue Therapy in Multi-Drug Resistant Crohn's Disease
-
(Suppl. 1)
-
Ginard D, Khorrami S, Marin-Jimenez I,. Effectiveness and Safety of Ustekinumab as Rescue Therapy in Multi-Drug Resistant Crohn's Disease. Gastroenterology 2012; 142 (Suppl. 1): S-355.
-
(2012)
Gastroenterology
, vol.142
-
-
Ginard, D.1
Khorrami, S.2
Marin-Jimenez, I.3
-
215
-
-
43449111187
-
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
-
DOI 10.1016/S0140-6736(08)60725-4, PII S0140673608607254
-
Leonardi CL, Kimball AB, Papp KA, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-74. (Pubitemid 351671883)
-
(2008)
The Lancet
, vol.371
, Issue.9625
, pp. 1665-1674
-
-
Leonardi, C.L.1
Kimball, A.B.2
Papp, K.A.3
Yeilding, N.4
Guzzo, C.5
Wang, Y.6
Li, S.7
Dooley, L.T.8
Gordon, K.B.9
-
216
-
-
79957519306
-
Pustular psoriasis development after initial ustekinumab administration in chronic plaque psoriasis
-
Gregoriou S, Kazakos C, Christofidou E, et al,. Pustular psoriasis development after initial ustekinumab administration in chronic plaque psoriasis. Eur J Dermatol 2011; 21: 104-5.
-
(2011)
Eur J Dermatol
, vol.21
, pp. 104-105
-
-
Gregoriou, S.1
Kazakos, C.2
Christofidou, E.3
-
217
-
-
79956034032
-
Exacerbation and change of psoriasis morphology in a patient treated with ustekinumab
-
Kerdel FA, Valeron-Almazan P, Vitiello M, et al,. Exacerbation and change of psoriasis morphology in a patient treated with ustekinumab. J Cutan Med Surg 2011; 15: 183-4.
-
(2011)
J Cutan Med Surg
, vol.15
, pp. 183-184
-
-
Kerdel, F.A.1
Valeron-Almazan, P.2
Vitiello, M.3
-
218
-
-
80053371455
-
Exacerbation of infliximab-induced palmoplantar psoriasis under ustekinumab therapy in a patient with ankylosing spondylitis
-
Safa G, Martin A, Darrieux L,. Exacerbation of infliximab-induced palmoplantar psoriasis under ustekinumab therapy in a patient with ankylosing spondylitis. J Clin Rheumatol. 2011; 17: 385-6.
-
(2011)
J Clin Rheumatol.
, vol.17
, pp. 385-386
-
-
Safa, G.1
Martin, A.2
Darrieux, L.3
-
219
-
-
84861079637
-
Flare of pustular psoriasis after initiating ustekinumab therapy
-
Wenk KS, Claros JM, Ehrlich A,. Flare of pustular psoriasis after initiating ustekinumab therapy. J Dermatolog Treat. 2012; 23: 212-4.
-
(2012)
J Dermatolog Treat.
, vol.23
, pp. 212-214
-
-
Wenk, K.S.1
Claros, J.M.2
Ehrlich, A.3
-
220
-
-
84858633545
-
An update on the long-term safety experience of ustekinumab: Results from the psoriasis clinical development program with up to four years of follow-up
-
Reich K, Papp KA, Griffiths CE, et al,. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol 2012; 11: 300-12.
-
(2012)
J Drugs Dermatol
, vol.11
, pp. 300-312
-
-
Reich, K.1
Papp, K.A.2
Griffiths, C.E.3
-
221
-
-
84859869815
-
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials
-
Gordon KB, Papp KA, Langley RG, et al,. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol 2012; 66: 742-51.
-
(2012)
J Am Acad Dermatol
, vol.66
, pp. 742-751
-
-
Gordon, K.B.1
Papp, K.A.2
Langley, R.G.3
-
222
-
-
84856975715
-
The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis
-
Young L, Czarnecki D,. The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis. Australas J Dermatol 2012; 53: 57-60.
-
(2012)
Australas J Dermatol
, vol.53
, pp. 57-60
-
-
Young, L.1
Czarnecki, D.2
-
223
-
-
43449139402
-
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
-
DOI 10.1016/S0140-6736(08)60726-6, PII S0140673608607266
-
Papp KA, Langley RG, Lebwohl M, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84. (Pubitemid 351671884)
-
(2008)
The Lancet
, vol.371
, Issue.9625
, pp. 1675-1684
-
-
Papp, K.A.1
Langley, R.G.2
Lebwohl, M.3
Krueger, G.G.4
Szapary, P.5
Yeilding, N.6
Guzzo, C.7
Hsu, M.-C.8
Wang, Y.9
Li, S.10
Dooley, L.T.11
Reich, K.12
-
224
-
-
74249094930
-
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis
-
Griffiths CE, Strober BE, van de Kerkhof P, et al,. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-28.
-
(2010)
N Engl J Med
, vol.362
, pp. 118-128
-
-
Griffiths, C.E.1
Strober, B.E.2
Van De Kerkhof, P.3
-
225
-
-
79955696994
-
Ustekinumab and herpes zoster
-
Failla V, Nikkels AF,. Ustekinumab and herpes zoster. Dermatology 2011; 222: 119-22.
-
(2011)
Dermatology
, vol.222
, pp. 119-122
-
-
Failla, V.1
Nikkels, A.F.2
-
226
-
-
84863778808
-
Herpes zoster in patients treated with biologicals
-
Failla V, Jacques J, Castronovo C, et al,. Herpes zoster in patients treated with biologicals. Dermatology 2012; 224: 251-6.
-
(2012)
Dermatology
, vol.224
, pp. 251-256
-
-
Failla, V.1
Jacques, J.2
Castronovo, C.3
-
227
-
-
77956289560
-
Alopecia areata developing parallel to improvement of psoriasis during ustekinumab therapy
-
Slowinska M, Kardynal A, Warszawik O, et al,. Alopecia areata developing parallel to improvement of psoriasis during ustekinumab therapy. J Dermatol Case Rep. 2010; 4: 15-7.
-
(2010)
J Dermatol Case Rep.
, vol.4
, pp. 15-17
-
-
Slowinska, M.1
Kardynal, A.2
Warszawik, O.3
-
228
-
-
84865013186
-
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis
-
Sandborn WJ, Ghosh S, Panes J, et al,. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367: 616-24.
-
(2012)
N Engl J Med
, vol.367
, pp. 616-624
-
-
Sandborn, W.J.1
Ghosh, S.2
Panes, J.3
-
229
-
-
84866156845
-
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
-
Kremer JM, Cohen S, Wilkinson BE, et al,. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 2012; 64: 970-81.
-
(2012)
Arthritis Rheum
, vol.64
, pp. 970-981
-
-
Kremer, J.M.1
Cohen, S.2
Wilkinson, B.E.3
-
230
-
-
84865587510
-
Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: Efficacy, renal function and safety at 1 year
-
Vincenti F, Tedesco Silva H, Busque S, et al,. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant 2012; 12: 2446-56.
-
(2012)
Am J Transplant
, vol.12
, pp. 2446-2456
-
-
Vincenti, F.1
Tedesco Silva, H.2
Busque, S.3
|